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Abstract 
Innate immune cells provide critical protection against pathogens and produce immune 
factors that drive adaptive sickness behaviors to facilitate recovery from acute illness and 
injury. Microglia, the resident innate immune cells in brain, recognize pathogens and danger 
associated molecular patterns, then express proinflammatory signaling molecules such as 
interleukin (IL)-1β, IL-6, and inducible nitric oxide synthase (iNOS). Aging is associated with 
chronic neuroinflammation that is represented by behavioral and cognitive impairment, and 
increased risk of neurodegenerative disease. Aging-associated inflammation is thought to shift 
microglia into a primed state that contributes to increased neuroinflammation and oxidative 
stress in the aging brain.  
Dietary broccoli and its derived bioactive sulforaphane (SFN) has potential use as a novel 
nutritional intervention to reduce aging-related neuroinflammation. Sulforaphane activates 
nuclear factor E2-related factor 2 (Nrf2), which induces antioxidant response element genes 
that regulate cellular redox balance. In animal models of neurodegeneration and brain trauma, 
activation of the Nrf2 pathway is protective, but its function in the aging brain has not been 
investigated.  
Microglial activity is reportedly mitigated by SFN, forming the basis for our hypothesis that 
SFN would attenuate elevated inflammatory markers in unstimulated aged microglia and in 
microglia treated with lipopolysaccharide (LPS). To test this hypothesis, microglia from adult 
and aged mice were isolated and treated in vitro with SFN ± LPS in order to investigate the 
effects of SFN on aged and LPS-stimulated microglia. In support of the hypothesis, SFN 
decreased IL-1β, IL-6, and iNOS in LPS-simulated microglia from adult and aged mice, and 
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tended to decrease basal IL-1β in aged microglia. Sulforaphane increased Nrf2 target genes 
were increased in both adult and aged microglia, and increased Nrf2 activity in the BV2 
microglia cell line.  
Based on SFN’s ability to reduce inflammatory markers in microglia, we hypothesized that 
acute exposure to SFN may attenuate neuroinflammation and sickness behavior in LPS-
challenged mice.  Mice were administered SFN for 3 d then challenged with LPS to mimic 
peripheral infection. Nrf2 target genes and inflammatory mediators in brain and liver mRNA 
were quantified after 6 h. In hippocampus and liver of mice that were treated with LPS, SFN 
decreased IL-1β and iNOS, but did not improve sickness behavior. This led us to hypothesize 
that longer exposure to SFN, such as could be attained through dietary supplement with 
broccoli, may have a more pronounced impact on sickness behavior. To test this hypothesis, 
adult and aged mice were fed control diet or diet containing 10% broccoli. After 28 d, mice 
were injected with saline or LPS, and sacrificed 24 h later. Broccoli diet improved glial reactivity 
markers in aged mice. However, broccoli diet did not reduce IL-1β in brain or liver of aged or 
LPS-challenged mice, and had no effect on sickness behavior.  
Collectively these data provide novel evidence that SFN supplementation and dietary 
broccoli may be a beneficial nutritional intervention to reduce inflammation that is associated 
with aging and with peripheral infection.  
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Chapter 1 - General Introduction and Justification 
During the past century, the United States population of adults over age 65 years has grown 
more rapidly than other age groups, and this trend is projected to continue. Between 2014 and 
2060, the population 65 years and older is expected to double, expanding from 46 million to 98 
million [1]. Additionally, the oldest-old population, representing those 85 years and older, is 
expected to increase substantially as the baby boomer generation ages [2]. Although the 
increase in elderly population represents significant health improvements and medical 
advances that have contributed to extended longevity, a longer lifespan presents additional 
healthcare challenges. Chronic diseases, frailty, and cognitive decline are encountered more 
frequently in advanced years, with an estimated 80% of elderly adults having at least one 
chronic health condition [2]. Still, heterogeneity in the effects of aging on individuals suggests 
that complex factors underlie the extent to which aging impacts physiological and cognitive 
function. The majority of the older population exhibits either mild decline in cognition and 
functional abilities or pathological aging that is exacerbated by chronic disease such as 
Alzheimer’s that may severely impact daily living. In searching for a mechanistic link between 
aging and decline in cognition and behavioral function, epidemiological studies indicate a 
correlation between inflammation and chronic diseases that are associated with aging, 
including neurodegeneration [3,4]. This is particularly informative, because studies using aged 
animal models indicate that aging is associated with heightened basal and inducible expression 
of proinflammatory cytokines which are implicated in cognitive impairment, prolonged sickness 
response, and depressive disorders [5-9]. Furthermore, advances in neuroimmunology reveal 
that bidirectional inflammatory signaling occurs between the brain and periphery, impacting 
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cognition and behavior, but that these signaling pathways may become dysregulated during 
aging [10-12].  
As the percent of the older population grows, the attention of aging research is increasingly 
drawn to interventions that will mitigate chronic health problems. While the determinants of 
healthy aging are undoubtedly multifaceted, nutrition is one component that has received 
much research interest as a factor that can be modulated to improve aging outcomes. 
Nutritional support for long-term brain health is a significant component of aging research, due 
to the growing body of evidence suggesting that dietary supplementation with antioxidant-rich 
fruit or vegetable extracts reverses aging-related cognitive decline [13]. Sulforaphane, a 
broccoli bioactive, has garnered interest as a potent stimulator of endogenous antioxidant 
pathways, and recent evidence suggests that it conveys anti-inflammatory properties as well. 
The overall objective of this dissertation was to determine the anti-inflammatory potential of 
supplemental sulforaphane and dietary broccoli in the context of aging and microglial-mediated 
neuroinflammation. 
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Chapter 2 - Review of the Literature 
2.1 Innate Immunity and the Aging Brain  
Inflammation is a physiological response to stimuli that are damaging to a host. The 
stimulus may be a bacterial or viral pathogen, oxidative stress, cellular damage, exposure to 
environmental toxins, or other pathogens and danger-associated signals [1-3]. The body 
responds to acute and chronic immune challenges through a carefully controlled system of 
immune cells and signaling pathways that allow the host to eliminate the inflammatory 
stimulus. Acute response to inflammatory stimuli is mediated through the innate immune 
system. The innate immune system is activated when endogenous or pathogenic ligands bind to 
pattern recognition receptors that recognize certain molecular patterns, but lack the elaborate 
specificity of the adaptive immune system. Receptor-mediated signaling cascades alert innate 
immune cells to eliminate pathogens by phagocytosis or initiate an inflammatory response 
through increased transcription of proinflammatory cytokines and release of reactive oxygen 
and nitrogen species [4].  
Neuroinflammation, which describes inflammatory processes that occur in the cells of the 
central nervous system (CNS), is a relatively modern term that was not widely referenced until 
the later 1990s. The distinction between inflammation and neuroinflammation is derived from 
the fact that immune mechanisms are strictly regulated in the brain, and to a great extent, set 
apart from the peripheral immune system by the blood brain barrier and lack of a central 
lymphatic system [5]. Neuroinflammation is regulated through interactions among neurons and 
glial cells, and initially was studied only in medical conditions that directly affected the CNS. 
However, the discovery that proinflammatory cytokine expression increased in the brain during 
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peripheral infection gradually expanded the understanding of neuroinflammation to comprise a 
bi-directional signaling network between the nervous system and the peripheral immune 
system. Several key pathways have been identified through which peripheral-to-brain 
communication occurs, namely the humoral and neural signaling pathways [6]. Because 
cytokines are generally too large to diffuse across the blood brain barrier, a humoral signaling 
pathway for circulating cytokines was considered plausible only at the circumventricular regions 
which lack a blood brain barrier, or through specialized cytokine transporters. Another 
hypothesis suggested that circulating cytokines outside the blood brain barrier induced 
synthesis of small molecule intermediates, such as prostaglandins, which can diffuse readily 
through the blood brain barrier and act as secondary messengers in the brain [7,8]. Although 
more recent evidence suggests that minimal cytokine leakage occurs through circumventricular 
organs, cytokine receptors and nerves at these sites facilitate the relay of peripheral immune 
signals to the brain [9]. Transporters for the proinflammatory cytokines interleukin (IL)-1β, IL-6, 
and tumor necrosis factor (TNFα) have also been identified in epithelial cells of the blood brain 
barrier, allowing tightly regulated signaling to occur through this barrier. Cytokines generated in 
the periphery also relay signals to the brain through the vagal nerve pathway that provides 
extensive neural communication from the gastrointestinal tract, liver, heart, lungs, and other 
organs [6,10]. Identification of IL-1 and prostaglandin receptors on vagal nerve endings 
supported the early hypothesis that peripheral cytokine signals could rapidly be transmitted to 
the brain through a neural pathway [11,12].  
Inflammatory status in both the brain and periphery is an important indicator of health and 
longevity. Evidence from clinical and pre-clinical research consistently points to age-related 
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alteration of inflammatory mechanisms that can result in chronic low-grade inflammation and 
onset of aging-related diseases [13-16]. Vulnerability to infection increases with age, and 
infection in elderly populations is often accompanied by mild cognitive impairment which leads 
to difficulty in self-care and prolonged recovery time [16-18]. Advanced age is also the primary 
risk factor for dementia and neurodegenerative disease, implying that the brain is highly 
sensitive to immunological changes that occur with aging [19,20]. Increased oxidative damage 
to proteins and DNA has been identified in brains of healthy aged patients as well as patients 
with Alzheimer’s disease, indicating that molecular changes are not restricted to presence of 
neurodegenerative pathology. [21-24].  
Experimental studies in lipopolysaccharide (LPS)-stimulated aged mice have demonstrated 
that both prolonged sickness behavior and cognitive impairment occurs in conjunction with 
increased proinflammatory markers in the brain, particularly in microglia, suggesting that this 
cell type may be an important mediator of aging-related neuroinflammation [25-28]. Changes in 
microglial morphology and function in the aging human brain further indicate that microglia 
may play an important role in brain aging [29].  
 
2.2 Microglia and Neuroinflammation 
Microglial involvement in brain pathology was mentioned as early as the 19th century when 
psychiatrist Franz Nissl described glial “stäbchenzellen” or rod-shaped cells that were motile, 
phagocytic, and present in neurodegenerative pathology [30]. Nearly twenty years after Nissl’s 
discovery, Pio del Rio-Hortega distinguished microglia from oligodendrocytes, neurons, and 
astrocytes, and further characterized their activation states [30]. Microglia are now often 
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referred to as the resident innate immune cells of the brain because of their rapid, multifaceted 
response to disruptions in homeostasis [31]. In a non-activated state, microglia are ramified 
cells with thin protruding processes that facilitate surveillance of their surroundings. In 
contrast, activated microglia adopt an amoeboid morphology. In addition to morphological 
variation, microglia display an amazing degree of functional plasticity. Older literature referred 
to quiescent, or resting microglia, that, when stimulated, transitioned into neurotoxic, activated 
microglia. However, the term “resting” is somewhat deceptive, because ramified microglia 
exhibit dynamic restructuring of their processes, providing a constant state of surveillance. It is 
thought that the microglial network is able to perform complete scans of the brain every 
several hours [32,33]. Like their peripheral counterpart, the macrophage, microglia are 
currently classified according to whether their activation state is polarized towards a 
proinflammatory (M1) or anti-inflammatory (M2) phenotype. Classical activation, which 
indicates the M1 phenotype, is stimulated in vitro by LPS or interferon-γ and is characterized by 
expression of proinflammatory cytokines such as IL-1β, IL-6, and TNFα [34]. Animal models of 
traumatic brain injury and stroke also initiate M1 activation [35-37]. Although M1 activation is a 
critical mechanism to protect neurons from invading pathogens, prolonged M1 activation is 
neurotoxic. Therefore, to resolve acute neuroinflammation, healthy microglia transition from 
the M1 phenotype to an M2, or alternative activation state. The M2 phenotype is associated 
with anti-inflammatory cytokines IL-13 and IL-4 and secretion of growth factors that support 
neuronal and tissue repair. The phenotypic reprogramming that occurs through M1 and M2 
polarization diversifies microglial response, equipping them for distinct functions [38,39].  
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Pattern recognition receptors and antigen presenting molecules facilitate the critical 
surveillance function of microglia. Like other peripheral immune cells, microglia express 
membrane-spanning toll-like receptors (TLRs). TLRs bind ligands that correspond to pathogen-
associated molecular patterns and signal microglia to stimulate an innate immune response. A 
variety of TLRs have been identified, with each TLR corresponding to different category of 
ligand pattern recognition. For example, TLR4 recognizes gram-negative bacterial LPS, leading 
to the popular use of LPS as a microglial immune stimulus. Activated TLR4 initiates a signaling 
cascade that results in proinflammatory signaling involving activation of TNFα and the 
proinflammatory transcription factor, NFκB [40]. In addition to TLRs, complement type-3 
receptor (CR3; CD11b/CD18) is a constitutively expressed pattern recognition receptor that 
comprises a subunit of the larger macrophage antigen complex-1 (MAC1). Complement type-3 
receptor is essential to initiation of phagocytosis that eliminates pathogens during acute 
inflammation. Additionally, the CD11b subunit is commonly used as an identifying microglia 
marker [41,42]. Another surface protein, major histocompatibility complex class II (MHC-II), is a 
membrane-bound, antigen-presenting protein that is expressed on microglia [43,44]. 
Expression of MHC-II and CD11b increase in response to immune stimuli and, interestingly, 
there is some evidence that both proteins are more highly expressed in aged animals compared 
to adults [45,46].  
Activated microglia are involved in nearly all described pathologies of the CNS, indicating 
that this cell type is highly sensitive to disruptions in homeostasis [47]. Some research suggests 
that microglial dysregulation occurs during aging, in which the microglia are resistant to the M2 
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phenotype. Therefore, microglia are often studied in context of aging, with particular attention 
given to mechanisms that regulate the M1 and M2 phenotypes.  
Aging leads to M1 priming in which mildly activated microglia are chronically sensitized to 
inflammation and produce an exaggerated response when challenged by a second immune 
stimulus [48-50]. Several studies have demonstrated increased basal levels of cytokines in 
microglia from aged mice, suggesting that primed microglia contribute to aging-related 
neuroinflammation [50,51]. In addition to the inflammatory milieu, aberrant microglial 
activation in aged mice is tied to impairment of social behavior and cognition [25,47,50,52-54]. 
Pharmacological and nutritional therapies that reduce microglial activation are therefore highly 
applicative to aging research [54,55].  
 
2.3 Cytokine-mediated Sickness Behavior 
Malaise, lethargy, fever, and anhedonia are classic sickness symptoms. Collectively, these 
symptoms represent a behavioral component of the acute phase response that immediately 
follows an immune challenge. Sickness behaviors that accompany common human illnesses, 
including colds and influenza, are associated with increased healthcare costs, absenteeism, and 
reduced ability to function normally in a professional or academic environment. Cognitive 
impairment and reduced psychomotor skills during sickness in older patients is accentuated 
compared to younger adults [56]. In older adults, depression and medical comorbidity is not 
uncommon, and may be reflective of a maladaptive sickness response to elevated cytokines 
[57].  
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The biological basis for sickness behavior was not identified until after the discovery of 
cytokine IL-1, when researchers noticed similarities between the side effects of systemic IL-1β 
administration and symptoms of peripheral infection [58]. This recognition was influential in 
understanding cytokine-mediated interconnections between behavioral patterns and 
immunology [59]. Once it became apparent that adaptive sickness behaviors were initiated by 
cytokines, researchers were better able to target cytokine signaling pathways using inhibitory 
modulators (i.e. cytokine receptor antagonists) to mitigate sickness responses [60,61].  
Cytokines comprise a diverse class of pro- and anti-inflammatory signaling peptides that are 
secreted by immune cells [62]. Although a number of cytokines contribute to the innate 
immune response, IL-1β has perhaps been the most widely studied for its role in mediating 
sickness behavior and cognitive impairment during an inflammatory response. IL-1β receptors 
are expressed in the brain, with regional variations indicating higher receptor density in areas 
such as the hippocampus [63]. Experimental models and clinical observations provide evidence 
of increased IL-1β transcripts in the brain following endotoxin exposure, ischemia, or brain 
injury, along with sickness behaviors including reduced social exploration and food intake 
[64,65]. Central administration of IL-1 receptor antagonist attenuates sickness behavior and 
reduces elevated IL-1β mRNA in the hippocampus of aged mice following a peripheral injection 
of LPS, confirming that peripheral immune stimulation is communicated to the brain, and 
indicating that central IL-1β is an important mediator of sickness behavior [66].  
The use of LPS injection as a model of peripheral infection has been an important 
component of studies involving cytokine-induced sickness behavior. In the early 1990s, the first 
paper was published reporting evidence of IL-1 staining in microglia following peripherally 
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administered LPS [58]. Since then, it has become common to use LPS to stimulate inflammation 
in both in vitro and in vivo models. Stereotypical sickness behaviors in response to subseptic 
doses of LPS have been defined in mice models to provide measurable parameters of sickness 
response and recovery. These include anorexia (reductions in food intake and loss of body 
weight), lethargy (decreased spontaneous locomotor activity), and anhedonia (reduced sucrose 
preference; decreased social investigation) [67]. As might be expected, animals recover from 
sickness behavior more rapidly after a low dose of LPS than after a high dose [68]. Additionally, 
recovery from LPS-induced sickness response is typically longer in aged mice than young adult 
mice. It is thought that age-related changes in the CNS, including increased microglial activity 
and exaggerated proinflammatory cytokine response, contribute to prolonged cytokine 
signaling and delayed recovery [27,49,69].  
Nutritional bioactives have been studied for their potential ability to inhibit sickness 
response or hasten recovery time in aged mice. The dietary antioxidant α-tocopherol, 
administered by intraperitoneal injection or incorporated into diet, did not affect peak sickness 
in mice challenged with low-dose LPS, but reduces recovery time [68]. Further examination 
revealed that α-tocopherol alleviated sickness behavior and was associated with reduced 
proinflammatory cytokine expression in the brain [70]. Quercetin, another dietary antioxidant 
that also upregulates antioxidant enzymes, also reduced the LPS-induced sickness response by 
attenuating proinflammatory cytokines and reactive oxygen species, increasing evidence in 
support of a link between antioxidant and anti-inflammatory mechanisms [71].  
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2.4 Oxidative Stress and the Nrf2 Pathway 
Oxygen has a long-standing association with aging due to its involvement in metabolic rate 
and its propensity to form highly reactive free radicals. In the 1920s, Raymond Pearl formulated 
the rate of living hypothesis, suggesting that high metabolic output decreases longevity. For 
instance, a rodent with seven times the metabolic rate of a human will age very quickly, 
comparatively. A quarter of a century later, Denham Harman introduced the free radical theory 
of aging, proposing that aging is a result of free radical reactions that are damaging to tissues. 
Although these theories have since been challenged and somewhat reformulated, oxidative 
stress is still a focal consideration that underlies aging-related deterioration of physiological and 
biochemical mechanisms [72-75]. Neurodegenerative disease, atherosclerosis, cancer, and a 
wide variety of other diseases typically associated with aging are linked to an imbalance in 
antioxidant status and ROS production [76,77]. In fact, as mice age there is a nearly linear 
increase in oxidative stress and associated cognitive deficits. Several in vivo studies have used 
various antioxidant treatments to investigate whether increased oxidative stress is an 
inevitable, damaging component of aging or a preventable symptom of aging. Based on the 
results from these studies, it seems that antioxidants that are chronically administered during 
the aging process prevent oxidative damage and impaired learning and memory. Others have 
demonstrated that subchronic administration of antioxidants partially reverses cognitive 
deficits in aged animals. However, once antioxidant exposure is withdrawn, oxidative stress and 
cognitive deficits return, suggesting that a chronic intervention is necessary to maintain aging 
brain health [78-83].  
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Free radicals, reactive oxygen species, and reactive nitrogen species are produced 
intrinsically by mitochondria and in phagocytic cells through complex systems such as NADPH 
oxidase and nitric oxide synthase [84,85]. Strategies to reduce oxidative stress using antioxidant 
supplements, caloric restriction, and other dietary methods are widely promoted as anti-aging 
therapy. The American public continues to funnel money into antioxidant supplements despite 
little evidence indicating that they improve longevity [86,87]. As an alternative to consuming 
antioxidant supplements to counteract age-related oxidative stress, it may be more effective to 
utilize pharmaceutical supplements or nutritional tools that activate the body’s endogenous 
antioxidant pathways.  
Transcriptional regulation of endogenous antioxidant enzymes through nuclear factor E2-
related factor 2 (Nrf2) is at the forefront of oxidative defense mechanisms and is a potential 
target for pharmacological and nutritional therapeutics. Nrf2 was isolated in 1994, some years 
after Talalay proposed the existence of a specific enzyme-inducing mechanism that regulated 
cytoprotective enzymes [88,89]. The newly identified protein was characterized as a 
transcription factor that forms heterodimers with small Maf proteins and binds to the 
antioxidant response element (ARE), a regulatory region that was known to promote expression 
of enzymes that neutralize reactive species or conjugate harmful metabolites to soluble 
compounds that are rapidly excreted [90]. Prior to the discovery of Nrf2, a diverse group of 
electrophilic chemical agents had been identified as ARE-inducing compounds, but it was 
unknown whether these compounds upregulated ARE genes through one dominant pathway or 
separate pathways [91,92]. Further exploration of the Nrf2 pathway revealed Nrf2-dependent 
increases in ARE gene expression, providing a unifying mechanism underlying inducible 
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expression of these genes. The laboratory of Yamamoto was one of the first to use homozygous 
Nrf2-deficient mice to further characterize Nrf2-dependent cellular protection. Importantly, 
their research demonstrated that dietary administration of the phenolic antioxidant butylated 
hydroxyanisole (BHA) resulted in Nrf2-mediated induction of the ARE-containing genes 
glutathione-S-transferase (GST) and NAD(P)H quinone oxidoreductase (NQO1) [93]. In support 
of this evidence, McMahon et al. demonstrated that Nrf2 was necessary for gastrointestinal 
upregulation of GST and NQO1 by a number of dietary compounds including BHA and the 
phytochemical sulforaphane. The knowledge that dietary compounds could induce ARE genes 
through Nrf2 provided a novel area for targeted nutritional intervention [94].  
Research has gradually uncovered various physiological and pathological states that are 
affected by Nrf2. Because the ARE promoter sequence is contained in many genes that are 
involved in prevention of chemical carcinogenesis, initial interest in Nrf2-mediated activation of 
the ARE genes was driven by the desire to induce anti-carcinogenic enzyme activity [93]. The 
ARE genes also include endogenous antioxidant enzymes, and many subsequent studies of Nrf2 
have focused on areas that are exposed to highly oxidative conditions. In the lung, for example, 
Nrf2 is a critical factor in resistance to damage induced by environmental toxins and cigarette 
smoke [95]. In the liver and gastrointestinal tract, Nrf2 protects against oxidative stress, 
xenobiotics, and carcinogens [96,97]. Over two hundred genes are regulated by Nrf2 in the liver 
alone, and its ubiquitous expression makes it a versatile therapeutic target for cancer and 
pathologies that are linked to oxidative stress [98,99].  
In 2006, Thimmulappa and colleagues published research that formed the framework for 
yet another significant aspect of Nrf2 function. This work presented evidence of Nrf2-blunted 
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peripheral inflammation following an acute LPS dose, demonstrating that Nrf2 modulates the 
innate immune response. In an experimental model of sepsis, innate immune system factors 
including signaling regulators, cytokines, and acute phase proteins, were elevated in Nrf2 
knockout mice compared to wild-type controls. Wild-type mice were also more resistant to high 
doses of LPS than the Nrf2 knockout mice [100].  
Several Nrf2 target genes have been extensively studied in the context of their 
cytoprotective properties. The flavoprotein NQO1 is a commonly used enzymatic biomarker for 
screening antioxidant, anti-carcinogenic compounds, and was a valuable tool in the initial 
characterization of Nrf2’s ARE-inducing function [101]. Ubiquitously expressed NQO1 serves as 
a defense mechanism against redox-reactive xenobiotics and endogenous reactive species that 
are generated by the electron transport chain. Two-electron reduction of quinones and reactive 
quinone metabolites is catalyzed by NQO1, effectively removing their toxicity. Additionally, 
NQO1 scavenges superoxide radicals and maintains tumor suppressor proteins [84,85,102]. 
Elevated NQO1 has been observed in hippocampi from Alzheimer’s disease subjects, indicating 
that its expression may be involved in a compensatory mechanism against the increased 
oxidative stress that is present in neurodegenerative pathology [103].  
Heme oxygenase 1 (HMOX1) is the rate-limiting enzyme in the degradation of heme, and is 
upregulated by transcription factors including Nrf2 [104]. Heme is a strong oxidant, and this 
reaction effectively neutralizes heme’s reactive potential and releases metabolites with strong 
antioxidant activity. Through the break-down of heme, HMOX1 contributes to normal cellular 
maintenance. Under oxidative stress conditions, HMOX1 is upregulated, enabling the cell to 
neutralize additional oxidants [105]. The critical detoxification role this enzyme is especially 
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apparent when HMOX1 is deficient. Oxidative stress elevates HMOX1 and results in a mild free 
radical increase in primary fibroblasts. In contrast, primary cells isolated from HMOX1 knockout 
mice are less resistant to oxidative stress. Mice deficient in HMOX1 also display markers of 
chronic inflammation [106]. There is some evidence that HMOX1 increases with age in liver 
which may represent a compensatory mechanism for increased oxidative stress [107,108].  
 
2.5 Nrf2 Pathway and Neuroinflammation 
Nearly a decade after Nrf2 was identified, its potential role in brain health emerged as a 
new research interest, stimulated by the clear relationship between increased oxidative stress 
and neurodegenerative pathology. Initial investigation using neuroblastoma cell lines and CNS-
derived primary cells detected a protective role for Nrf2 against oxidative stress and 
neurotoxins [109,110]. Basal expression of NQO1 is more reduced in brain and liver of Nrf2 
knockout mice than in wild-type controls, suggesting that Nrf2 target genes are involved in 
antioxidant response in central as well as peripheral tissues. Loss of Nrf2 also exaggerates 
neuroinflammation and is accompanied by reduced neurological function in animal models of 
traumatic brain injury and neurotoxicity. Additionally, Nrf2 seems to be essential to basal and 
inducible expression of ARE genes in the brain [111-113]. Interestingly, the Nrf2-activator 
sulforaphane (SFN) mitigates damage from traumatic brain injury, presumably by upregulation 
of ARE genes and reduction of injury-associated oxidative stress [114-116].  
Deficiency in Nrf2 increases glial reactivity in a mouse model of experimental Parkinson’s 
disease. In particular, microglia cultured from these mice displayed elevated activation markers 
and loss of inducible ARE gene expression [117]. Clinical research has gathered some evidence 
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of low Nrf2 protein levels in patients with neurodegenerative disorders, particularly in brain 
areas associated with onset of disease symptoms, suggesting the interesting possibility that a 
dysfunctional Nrf2 system is involved in neurodegenerative pathology [118,119]. Despite these 
advancements in understanding the functions of the Nrf2 pathway in the brain, little is known 
about Nrf2 involvement in age-related neuroinflammation. 
 
2.6 Nutrition and Neuroinflammation 
Nutrition is a key predictor of overall health and a critical factor in disease prevention [120]. 
Nutritional research involves development of mechanistic and translational information about 
dietary components that can be used to equip an individual with the best possible biochemical 
tools to avoid illness or recover from sickness and injury. Nutrition is necessary for sustaining 
brain health, from providing macronutrients that maintain brain structure and supplying 
glucose that supports brain metabolism, to micronutrients such as the B vitamins that are 
critical to neurotransmission. Increased availability of literature describing integrated nutrition 
and brain research implies an expanding interest in nutritional links to cognition and behavior. 
For example, it has long been recognized that dietary intake of caffeine and other 
psychostimulants have a powerful effect on alertness and cognition, but for a long time, this 
view was a common sense realization rather than a mechanistic understanding [121]. More 
recently, researchers have increased their efforts to elucidate biochemical pathways related to 
nutrition and long-term brain health, while others tested outcomes of dietary patterns and 
bioactive supplementation on brain function across the life stages. One significant development 
that has arisen is the realization that nutrition affects the interrelationship between the 
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immune system and the nervous system. Nutrition is now viewed as a tool to manipulate anti- 
and proinflammatory pathways that impact the brain. Diets rich in omega-3 fatty acids and 
phytonutrients from vegetables and fruits supply antioxidants that reduce oxidative stress and 
inflammation, while diets high in processed foods promote inflammation. Epidemiological 
studies indicate that healthier diet styles are associated with reduction of depression, lowered 
risk of neurodegenerative diseases, and improvement in cognitive function [122,123].  
Nutrition impacts long-term brain health, and it is well-documented that incorporation of 
essential nutrients and bioactives into a dietary routine influences physiological and 
psychological parameters that benefit cognition and behavior [124]. Recent studies indicate 
that resveratrol, a phytochemical found in red wine, decreases the effects of LPS-induced 
sickness behavior and increases learning and memory in aged mice [25].  Luteolin, a flavonoid 
obtained from celery, reduces proinflammatory cytokine production in reactive microglia, 
which may support healthy brain aging [54]. Phytochemicals from berries also convey 
neuroprotective support to aged rodent models, by increasing antioxidant activity and reducing 
inflammation [125]. Collectively, these studies point to a beneficial aspect of nutritional 
bioactives in mitigating the adverse aging-related effects of neuroinflammation.  
 
2.7 Clinical and Nutritional Relevance of Sulforaphane 
Cruciferous vegetables are remarkably suited for health-promoting effects due to their 
nutrient and bioactive profile, and frequent intake is correlated with reduced risk of cancer. 
Broccoli, cabbage, kale, Brussels sprouts, and other crucifers store glucosinolates, parent 
compounds to isothiocyanates which inhibit carcinogen formation and activate enzymes that 
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facilitate detoxification [55,126,127]. Bioactive SFN is derived from its glucosinolate parent 
compound, glucoraphanin. Broccoli and broccoli sprouts are especially rich producers of 
glucoraphanin, which is hydrolyzed to SFN by the enzyme myrosinase. Myrosinase is produced 
by the plant, compartmentalized separately from glucoraphanin, which prevents SFN formation 
until cell walls are broken down by crushing, milling, or chewing broccoli. Colonic bacteria also 
produce enzymes with thioglucosidase activity that can hydrolyze glucoraphanin to SFN 
[126,128,129].  
Analysis of glucosinolate concentrations in broccoli reveals large varietal differences. 
Storage and processing conditions also affect glucosinolate stability and myrosinase activity, 
making these significant factors in the amount of SFN that can be hydrolyzed from broccoli. 
Commercially-produced frozen broccoli lacks active myrosinase and converts little to none of 
the glucoraphanin to SFN. Because myrosinase is heat-sensitive, processing methods that 
include blanching, microwaving, or steaming > 60°C renders SFN unavailable. In contrast, 
dehydration or freeze-drying methods prevent heat-inactivation of myrosinase [130-132]. 
Appropriate cooking or processing methods for dietary and supplemental broccoli are 
important in order to prevent loss of SFN bioavailability. Raw broccoli has higher SFN 
bioavailability and peak plasma concentrations are reached in less time compared to 
microwaved broccoli [133,134]. Pharmacokinetic studies demonstrate that purified SFN, 
administered intravenously or orally, is very well absorbed at dietary doses, with peak plasma 
concentrations reached after an hour and complete clearance within 24 h [135]. SFN is also 
widely distributed, with metabolites detected in brain and peripheral tissues several hours after 
oral gavage [136].  
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The well-characterized ability of SFN to reduce oxidative tissue damage encompasses the 
liver, pancreas, lung and airway, heart, skeletal muscle, retina, and brain. In addition, SFN has 
been studied extensively in vitro for its ability to suppress tumor development signals through 
inhibition of carcinogen-promoting Phase I enzymes and regulation of genes controlling 
differentiation and cell division [137,138]. In vivo, SFN increases transcription and activity of 
Phase II detoxification enzymes in colon, liver and mammary gland [132,139]. While purified, 
chemically-synthesized SFN is commonly used in cell culture treatments and for non-dietary 
routes of administration in animal models, several research groups have investigated health-
promoting benefits of broccoli or broccoli sprout-supplemented diet. Dietary broccoli conveys 
protection against environmental toxins, carcinogens, and oxidative damage that could result in 
cancer, hypertension, and atherosclerosis [140-142]. Increasing evidence suggests that diets 
high in SFN increase antioxidant enzyme activity and cytoprotective pathways in colon, 
prostate, kidney, and bladder tissues. Several mechanistic studies provide evidence that 
changes incurred are dependent on Nrf2 activation, as SFN loses its chemopreventive, 
antioxidant-inducing effect in small intestine, stomach, and liver of Nrf2 knockout mice 
[99,143].  
Elevation of Nrf2 target genes and reduced oxidative stress in the brain have also been 
reported following SFN treatment, in some cases up to days after a single dose or short-term 
repeated administration [144]. Sulforaphane administration prior to ischemia activates Nrf2 in 
the blood brain barrier and in perivascular astrocytes, effectively protecting the system from 
stroke-induced oxidative stress [145]. Growing interest in SFN’s ability to protect brain health 
has led to several interesting findings. One research group reported that SFN induced Nrf2 in 
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striatum and cortex, while another group investigated the ability of SFN to induce HMOX1 
expression in neurons and astrocytes [115,146]. Currently there is only limited data 
demonstrating SFN’s ability to improve cognitive function following brain injury [145,147], and 
SFN’s effect on cognitive and behavioral impairment in an aging model has not been 
investigated. It is, however, becoming more widely established that SFN attenuates 
inflammation in the CNS, in part by activating the Nrf2 pathway in microglia [144,148]. Thus, 
this phytochemical may be an effective activator of antioxidant and anti-inflammatory 
mechanisms that could support healthy brain aging.  
 
2.8 Summary and Objectives 
 Scientific advances over the past two decades have generated a well-characterized 
understanding of the relationship between cytokines, neuroinflammation, and sickness 
behavior [149]. Notably, elevated cytokines and microglial activation in aging have been linked 
to behavioral and cognitive impairment, which mirrors increased inflammation and mild 
cognitive decline in otherwise healthy elderly individuals. Bioactives such as SFN are targets for 
aging therapy due to their ability to attenuate inflammation and activate endogenous 
antioxidant pathways. To date, the majority of research involving SFN and dietary broccoli has 
focused on chemoprevention and, more recently, neuroprotection against traumatic brain 
injury and ischemia. While it has been theorized that SFN supplementation may improve long-
term brain health, its impact on the non-diseased aging brain has not been investigated. This 
dissertation was designed to examine whether SFN could attenuate markers of inflammation 
and oxidative stress in microglia, and whether these effects were associated with reduced 
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inflammation in the aging brain. In addition, a broccoli-supplemented diet was investigated as a 
potential intervention for LPS-induced sickness behavior and cytokine response in aged mice. 
These experiments provide important insight into the effects of SFN as a nutritionally relevant 
intervention to target inflammation in the aging brain.   
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Chapter 3 - Sulforaphane induces Nrf2 target genes and attenuates 
inflammatory gene expression in microglia from brain of young and aged mice 
3.1 Abstract 
Increased neuroinflammation and oxidative stress resulting from heightened microglial 
activation is associated with age-related cognitive impairment, neurodegenerative disease, and 
prolonged sickness response to an immune stimulus. The primary compensatory mechanism for 
neutralizing oxidative stress is through the nuclear factor E2-related factor 2 (Nrf2) pathway 
which induces transcription of antioxidant response element (ARE) genes. Here, BV2 microglia 
and brain CD11b+ microglial cells isolated from young adult and aged mice were used to 
investigate the effects of sulforaphane (SFN), a potent Nrf2-activating bioactive, on 
inflammatory gene expression associated with aging and lipopolysaccharide (LPS) stimulation. 
We hypothesized that SFN would activate the Nrf2/ARE pathway in BV2 microglia and primary 
microglia and attenuate elevated proinflammatory cytokine expression resulting from aging 
and LPS stimulation. In support of our hypothesis, SFN increased Nrf2 DNA-binding activity and 
upregulated ARE genes in BV2 microglia, while reducing LPS-induced interleukin (IL-)1β, IL-6, 
and inducible nitric oxide synthase (iNOS). In primary microglia from adult and aged mice, SFN 
increased expression of ARE genes and attenuated IL-1β, IL-6, and iNOS induced by LPS. Taken 
together these data indicate that SFN is a potential therapeutic supplement that may be 
beneficial for reducing microglial mediated neuroinflammation and oxidative stress associated 
with aging.  
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3.2 Introduction 
Microglia are activated in response to inflammatory stimuli and stress. Activated microglia 
produce proinflammatory cytokines and reactive oxygen and nitrogen species, and express 
genes associated with the newly defined microglial sensome [1,2]. Another factor that results in 
microglial activation is aging. Microglia from old but otherwise healthy mice tend to transition 
from the quiescent M0 phenotype to the inflammatory M1 phenotype [3]. This shift in 
microglial phenotype results in chronic, low grade neuroinflammation which is considered a 
contributing factor to some aspects of cognitive aging. Furthermore, microglia from aged mice 
are hypersensitive to stress and peripheral immune stimuli and produce excessive levels of 
inflammatory mediators when further provoked. Microglial hypersensitivity leads to prolonged 
behavioral deficits (i.e. sickness behavior) following peripheral infection [4,5]. This suggests that 
it is necessary to regulate the proinflammatory status of microglia in the aged brain to promote 
successful aging.  
Nuclear factor E2-related factor 2 (Nrf2) provides a critical compensatory mechanism to 
counteract oxidative stress through its ability to upregulate genes containing the antioxidant 
response element (ARE) promoter sequence [6]. Involvement of Nrf2 in regulation of 
inflammation and microglial activation has also been reported [7,8]. Because the Nrf2/ARE 
pathway can be activated by pharmacological and dietary sources, it has become a potential 
therapeutic target for reducing oxidative stress associated with chronic, age-related 
neuroinflammation [7,9,10].  
Sulforaphane (SFN) is a small-molecule Nrf2 activator that can be obtained naturally from 
cruciferous vegetables, with especially high concentrations derived from broccoli and broccoli 
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sprouts [11,12]. Clinical and pre-clinical studies have established that SFN from broccoli is 
readily absorbed [13] and has a low toxicity profile, making it suitable to be provided in 
supplement form [14,15]. However, in a recent study where a 10% broccoli diet was fed to aged 
mice, several markers indicative of reduced glial cell activity were altered, but other markers of 
inflammation were not [16]. Other studies suggest that Nrf2 signaling might be disrupted 
during aging, leading to decreased endogenous antioxidant response [17,18], but this has not 
been examined in microglia. Therefore, the aim of this study was to determine if SFN mitigates 
markers of neuroinflammation in primary microglia from young adult and aged mice. We 
hypothesized that SFN would activate Nrf2 target genes and reduce production of inflammatory 
mediators in microglia from adult and aged mice.  
 
3.3 Materials and Methods 
BV2 cell culture and treatments 
The immortalized murine microglia cell line, BV2, has been used as a model to investigate 
the neuroimmune system [19,20]. Cells were maintained at 37°C under 5% CO2 in 75-cm2 flasks 
in Dulbecco modified Eagle medium (Lonza, Allendale, NJ) supplemented with 10% fetal bovine 
serum (FBS) (Hyclone, Logan, UT), 200 mM glutamine, and streptomycin/penicillin (Invitrogen, 
Carlsbad, CA). In order to determine time-dependent change in ARE gene expression, cells were 
treated with vehicle (complete medium) or 2.5 µM SFN (LKT Laboratories, St. Paul, MN) for 3, 6, 
9, or 24 h. In subsequent experiments, cells were treated for 1 h with SFN or vehicle, then with 
PBS ± LPS (100 ng/mL) (Sigma, St. Louis, MO; 0127:B8) for 8 h. Each treatment was replicated 3 
times in separate but identical trials.  
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CD11b+ microglia cell isolation and culture 
Because microglial cell activity is closely tied to brain health, it is important to study this 
specific cell type in the context of aging and exposure to an immune stimulus. In order to obtain 
primary microglia, we used an isolation method slightly modified from a protocol previously 
described that yields an enriched population of CD11b+/CD45low microglia that retain 
phenotypic integrity and inflammatory cytokine production in response to LPS [21]. Cells that 
were positive for CD11b were isolated from brains of young adult (4-5 month old, n = 16) and 
aged (19-20 month old, n = 16) BALB/c mice. Whole brains were enzymatically digested using a 
Neural Tissue Dissociation Kit (Miltenyi Biotec, San Diego CA) for 35 min at 37°C. Digested 
tissue was then passed through a 40 µm strainer to further separate cells and remove debris 
and then pelleted by centrifugation at 300 x g for 15 min. Myelin removal was facilitated by 
suspending the pelleted cells in 30% Percoll-Plus (GE Healthcare, Princeton, NJ) and centrifuging 
for 10 min at 1000 x g. After centrifugation, myelin and percoll were aspirated and remaining 
cells were washed with PEB solution consisting of sterile PBS, 0.5% BSA and 0.2 mM EDTA. Cells 
were then pelleted by centrifugation, PEB solution was removed, and cells were incubated with 
anti-CD11b magnetic microbeads (10 µL beads 90 µL PEB; Miltenyi Biotec, San Diego CA) for 15 
min. MS columns were used to magnetically separate CD11b+ cells (Miltenyl Biotec, San Diego 
CA). Cells were collected and suspended in medium (DMEM, 10% FBS) containing 10 ng/mL 
GM-CSF and plated in 12-well culture plates pre-coated with poly-L-ornithine (Sigma, St. Louis, 
MO). After 7-8 days in culture, primary cells were treated and harvested. All primary cells were 
treated with vehicle (medium) ± SFN (2.5 µM) for 1 h followed by PBS ± LPS (10 ng/mL) for 8 h.  
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Nrf2 DNA-binding assay 
 The TransAm Nrf2 kit was used to measure Nrf2 nuclear protein binding to the ARE 
promoter sequence (Active Motif, Carlsbad, CA). BV2 cells were treated with SFN ± LPS as 
described above, then harvested with 0.25% Trypsin-EDTA and washed once with cold PBS. 
Cells were pelleted by centrifugation for 5 min at 500 x g. Nuclear proteins were extracted using 
NE-PER reagent (Pierce, Rockford, IL). Nuclear protein was quantified using the 660 nm Protein 
Assay Reagent from Pierce (Rockford IL) and 4.5 µg of nuclear protein per sample was used for 
the assay.  
 
Markers of inflammation and oxidative stress 
RNA was isolated from BV2 cells using E.Z.N.A. total RNA (Omega Biotek, Norcross, GA). 
RNA from primary microglia was isolated using the Tri Reagent protocol (Sigma, St. Louis, MO). 
Synthesis of cDNA was carried out using a high capacity RT kit (Applied Biosystems, Grand 
Island, NY) according to the manufacturer’s instructions. Quantitative real-time RT-PCR (qPCR) 
was used to detect changes in mRNA expression of ARE genes NQO1 (Mm.PT.56a.9609207), 
HMOX1 (Mm.PT.56a.9675808), and GCLM (Mm.PT.56a.11654780), and proinflammatory 
markers IL-1β (Mm.PT.56a.41616450), IL-6 (Mm.PT.56a.13354106), and iNOS 
(Mm.PT.56a.43705194) using PrimeTime qPCR Assays (Integrated DNA Technologies, Coralville, 
IA). All mRNA expression changes were compared to the housekeeping control gene GAPDH 
(Mm.PT.39.a.1) and the 2-ΔΔCt calculation method as previously described [22]. Data are 
expressed as fold change relative to the adult vehicle control.  
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To determine whether SFN attenuated secretion of proinflammatory cytokines, media from 
BV2 cells and primary microglia were collected 9 h after SFN. IL-6 protein expression was 
quantified using a commercially available OptEIA ELISA kit (BD Biosciences, San Jose, CA) 
according to manufacturer’s instructions.  
Nitrite production in medium from treated BV2 cells was measured using the Promega 
Griess Reagent System (Madison, WI). The assay was conducted according to the 
manufacturer’s instructions. Absorbance was read at 532 nm.  
 
Statistical analyses  
All data were analyzed using Statistical Analysis System (SAS, Cary, NC). Data from BV2 cells 
were subjected to two-way analysis of variance (ANOVA) to assess main effects of SFN by time, 
or effects of SFN and LPS. Primary microglia data were analyzed using three-way ANOVA (Age, 
SFN, LPS). Where ANOVA revealed a significant interaction, post hoc Student’s t test using 
Fisher’s least significant differences was used to determine means separation. All data are 
expressed as means ± SEM.  
 
3.4 Results 
SFN increased expression of ARE genes in BV2 cells  
Because upregulation of antioxidants may contribute to SFN’s anti-inflammatory potential, 
we measured the transcriptional ARE response to SFN in BV2 cells. SFN upregulates ARE genes 
including NAD(P)H quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HMOX1), and the 
modulatory subunit of glutamate-cysteine ligase, modifier subunit (GCLM) [23]. We assessed 
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NQO1, HMOX1, and GCLM mRNA at four time points to determine the optimal time of gene 
induction. As shown in Figure 3.1, NQO1 was increased at 6, 9, and 24 h after SFN (p < 0.0001, 
for each) compared to vehicle controls. HMOX1 was increased at 3, 6, and 9 h after SFN (p < 
0.0001, for each) while GCLM was increased at 3, 6, 9, and 24 h after SFN (p < 0.0001, for each). 
These data indicate that the BV2 microglia cell line is highly responsive to SFN.  
 
SFN increased Nrf2 DNA-binding activity and decreased proinflammatory markers in BV2 cells 
Activation of Nrf2 in response to oxidative stress or chemical inducers results in its 
translocation to the nucleus where it regulates antioxidant genes by binding to the ARE 
promoter region [6]. Both SFN (p < 0.05) and LPS (p < 0.05) increased Nrf2 activity in BV2 cells 
(Figure 3.2) but the effects were not additive (SFN x LPS, p = 0.74).  
 In order to examine inhibitory effects of SFN on LPS-induced inflammation, the expression 
of several proinflammatory markers was assessed. As anticipated, LPS increased IL-1β, IL-6, and 
iNOS mRNA (p < 0.01, for each) (Figure 3.3). Importantly, SFN decreased LPS-induced IL-1β (p < 
0.05), IL-6 (p < 0.01), and iNOS (p < 0.0001).  
To determine if the change in mRNA expression was reflected by a change in protein, IL-6 
protein was measured in supernatants. Consistent with its effects on IL-6 mRNA, SFN reduced 
IL-6 protein secretion by LPS-treated cells (p < 0.05) (Figure 3.3). IL-1β protein is not secreted by 
BV2 cells and was therefore not assayed. Finally, SFN was found to inhibit nitric oxide 
production by LPS-stimulated BV2 cells, as measured by the Griess assay (p < 0.0001).  
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SFN increased expression of ARE genes in primary microglia from adult and aged mice 
 Although SFN-induced ARE gene expression has been previously reported in microglia 
[24,25], it has not been determined whether aging microglia are sensitive to the antioxidant-
inducing effects of SFN. This is important because dysfunctional Nrf2 signaling may underlie 
age-related changes reported for microglia. To address this question, microglia isolated from 
adult and aged mouse brain were treated with SFN for 9 h. Exposure to SFN increased NQO1, 
HMOX1, and GCLM mRNA of adult and aged microglia (p < 0.0001, for each) (Figure 3.4), and 
LPS further stimulated HMOX1 expression in SFN-treated microglia (SFN x LPS, p < 0.01). 
Additionally, SFN increased GCLM in aged microglia more than adult microglia (Age x SFN, p < 
0.05). These data confirm that primary adult and aged microglia had increased ARE gene 
expression following exposure to SFN similar to that observed in BV2 microglia. Moreover, 
microglia from aged mice responded to SFN similarly to microglia from adult mice.  
 
SFN decreased LPS-induced proinflammatory markers in primary microglia from adult and aged 
mice 
The aging brain displays persistent microglial activity which is thought to contribute to 
chronic, low-grade neuroinflammation that negatively impacts long-term brain health [26]. 
Because the previous study demonstrated that microglia from aged mice were responsive to 
SFN, we next examined if exposure to SFN would reduce inflammation in LPS-treated primary 
microglia from aged mice. As shown in Figure 3.5, LPS increased proinflammatory cytokines IL-
1β and IL-6 (p < 0.0001, for each). Interactions between SFN and LPS (p < 0.0001) were evident 
for IL-1β and IL-6, providing evidence that SFN reduces LPS-induced proinflammatory markers 
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in aging microglia. Consistent with the changes observed in IL-6 mRNA, SFN also inhibited LPS-
induced secretion of IL-6 (SFN x LPS interaction, p < 0.0001) in primary microglia. Because iNOS 
is induced by proinflammatory cytokines such as IL-1β, we examined the possibility that SFN 
could indirectly reduce oxidative stress by inhibiting iNOS expression [27]. In agreement with 
the reduction in LPS-induced IL-1β expression in SFN-treated aged microglia, SFN attenuated 
LPS-induced increase in iNOS mRNA (SFN x LPS interaction, p < 0.0001).  
 
3.5. Discussion  
Heightened microglial activation contributes to the chronic low-grade neuroinflammation 
that is evident in the elderly [28,29]. Due to the rapidly expanding aging population, coupled 
with the numerous detrimental effects of chronic neuroinflammation such as decreased 
cognition, research investigating nutritional and pharmacological means to reduce 
neuroinflammation has garnered increasing interest. The data presented here demonstrated 
that microglia from aged mice respond to SFN with induction of ARE genes, and that SFN is a 
potent inhibitor of LPS-induced inflammation and oxidative stress. Therefore, the present study 
suggests that SFN supplementation may be a viable strategy to reduce age-related 
neuroinflammation.  
Microglia are major producers of inflammatory mediators that exacerbate the production of 
reactive oxygen and nitrogen species in the CNS [30]. To counter oxidative stress, microglia, 
along with other cells of the CNS, produce endogenous antioxidants that are regulated 
predominately through the Nrf2/ARE pathway. Our initial experiments utilizing BV2 microglia 
sought to demonstrate that exposure to SFN is an effective treatment to increase expression of 
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ARE genes. The data obtained using BV2 microglia confirmed that ARE gene expression is 
increased in the presence of SFN and this is consistent with a previous study [24] that showed 
increased Nrf2 protein expression in BV2 cells after 9 h of exposure to SFN. Interestingly, our 
study revealed increased Nrf2 activity and induction of Nrf2 target genes using a much lower 
dose of SFN (2.5 µM compared to 50 µM) than used by Konwinski. 
The current study was to determine if SFN could upregulate ARE genes in primary microglia 
from aged mice. Here, we are the first to provide evidence that SFN increased NQO1, HMOX1, 
and GCLM transcription in aged mouse microglia. These data indicate that the mechanisms 
responsible for ARE gene induction are responsive to SFN, a potent Nrf2 pathway inducer, in 
aging microglia. This finding is particularly important because the progression of age-related 
cognitive decline and neurodegenerative pathologies is closely associated with increased 
oxidative stress and microglial activation [31-33]. Additionally, some evidence points to loss of 
Nrf2 activity during aging, which leads to reduced expression of endogenous antioxidants 
[17,18]. A dysregulated Nr2 pathway could render aged microglia more prone to take on an 
inflammatory state. However, studies reporting age-related loss of Nrf2 activity have focused 
on astrocytes and liver tissue [17,18,34,35], suggesting that there may be regional or cell-
specific differences in the aging Nrf2 pathway. The present study found no evidence that the 
Nrf2 pathway was affected in microglia from aged mice. While it is possible that the aged mice 
(20-22 mo) were not old enough for loss of Nrf2 activity to be detected, this is unlikely as age-
related phenotypic changes have been previously demonstrated in microglia from mice 
younger than those used in this study (18-20 mo) [5]. Nonetheless, an important finding is that 
the Nrf2/ARE pathway was intact in aged microglia, meaning that SFN may be useful for 
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decreasing microglial-mediated neuroinflammation and inducing endogenous antioxidant 
expression through the Nrf2 pathway.    
An additional benefit of SFN supplementation may be derived from reduction in 
proinflammatory mediators following activation of the Nrf2/ARE pathway. SFN has been 
reported to reduce inflammation in a Nrf2-dependent manner. Sulforaphane inhibits elevated 
inflammatory cytokines in wild-type macrophages, but has no known anti-inflammatory effect 
on cells lacking Nrf2 [36]. Upregulation of the Nrf2 pathway in endothelial cells prevented 
hydrogen peroxide induced oxidative toxicity and reduced inflammation by suppressing 
activation of the MAPK pathway [37]. Further, Nrf2-mediated inhibition of P38 phosphorylation 
reduced inflammatory cytokines in a BV2 model of neuroinflammation [38]. Here, we 
demonstrate that SFN attenuated the LPS-induced expression of cytokines IL-1β and IL-6 in 
primary microglia from aged mice. These proinflammatory markers are linked to sickness 
behavior and increased frailty during aging. Additionally, oxidative stress contributes to the 
neuroinflammatory milieu, both as a result of decreased antioxidant capacity, and increased 
oxidative damage. This increase in oxidative stress is associated with cognitive decline [31,39]. 
Within the CNS, upregulation of iNOS is an important oxidative component of the microglial 
inflammatory response to toxins and pathogenic stimuli, but excessive production of nitric 
oxide can damage surrounding cells [40,41]. We observed that SFN attenuated upregulation of 
iNOS in microglia from aged mice, supporting our hypothesis that the antioxidant-enhancing 
effect of SFN attenuates increased oxidative stress in stimulated aging microglia. Due to the 
limited microglia that can be isolated from a single mouse brain, we were unable to detect 
secreted nitrate as an indication of nitric oxide production. However, in BV2 cells, LPS induced 
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secretion of nitrate was substantially reduced by SFN, supporting the observed reduction of 
iNOS mRNA. 
Aged microglia are characteristically less responsive to anti-inflammatory signals compared 
to adult microglia, thus activation of alternative signaling pathways and transcriptional 
regulation using SFN may offer a unique approach for reducing neuroinflammation during aging 
[42]. Although our studies used ex vivo SFN treatment, peripherally administered SFN has been 
shown to cross the blood brain barrier and reduce microglial-mediated inflammation and 
oxidative stress in adult mice [7]. Our current data further demonstrate SFN’s anti-
inflammatory properties, specifically with regard to microglia isolated from aged mice. Previous 
studies have demonstrated that elevated neuroinflammatory mediators are found in brain 
tissue of otherwise healthy aged animals, implying a dysregulated neuroimmune status 
independent of disease [4]. Although our data did not reveal a main effect due to age, basal 
expression of IL-1β, IL-6, and iNOS were several-fold higher in aged control microglia compared 
to adult controls, in agreement with previous reports of heightened basal inflammatory 
markers in microglia [43]. These results indicate that proinflammatory markers in aging 
microglia are reduced by SFN, highlighting the need for future in vivo studies examining SFN 
induced attenuation of microglial-mediated inflammation.  
In summary, the data presented here indicate that SFN attenuates expression of IL-1β, a key 
proinflammatory cytokine involved in neuroinflammatory signaling. SFN also reduced 
proinflammatory cytokine IL-6 and oxidative stress marker iNOS. These data support the 
hypothesis that SFN can be used therapeutically to reduce potentially adverse properties of 
activated aging microglia. Furthermore, because neuroinflammation is closely associated with 
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deficits in cognitive abilities and behavioral function [44-46], an intervention such as SFN that 
reduces microglial-mediated inflammation may be advantageous to preventing age-induced 
decline in brain health.  
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3.6 Figures 
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Figure 3.1. SFN increased expression of ARE genes in BV2 cells. SFN increased NQO1, HMOX1, 
and GCLM. Bars represent means ± SEM (n = 3). Means with different letters are significantly 
different from each other (p < 0.05).  
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Figure 3.2. SFN increased Nrf2 activity in BV2 cells. SFN increased Nrf2 DNA-binding activity. 
Bars represent means ± SEM (n = 3). * indicates main effect of SFN and + a main effect of LPS (p 
< 0.05).  
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Figure 3.3. SFN decreased proinflammatory markers in BV2 cells. (A-C) SFN decreased LPS-
induced IL-1β, IL-6, and iNOS mRNA. (D-E) SFN decreased LPS-induced IL-6 protein and nitrite 
equivalents. Bars represent means ± SEM (n = 3). Means with different letters are significantly 
different from each other (p < 0.05). 
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Figure 3.4. SFN increased expression of ARE genes in adult and aged primary brain microglia. 
SFN increased NQO1, HMOX1, and GCLM mRNA. Bars represent means ± SEM (n = 4). Means 
with an asterisk indicate main effect of SFN (p < 0.0001). Means with different letters are 
significantly different from each other (p < 0.05). 
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Figure 3.5. SFN reduced proinflammatory markers in primary microglia from adult and aged 
mice. SFN decreased LPS-induced IL-1β, IL-6, and iNOS mRNA. Bars represent means ± SEM (n = 
4). Means with different letters are significantly different from each other (SFN x LPS, p < 
0.0001). 
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Chapter 4- Sulforaphane reduces lipopolysaccharide-induced proinflammatory 
markers in hippocampus and liver but does not improve sickness behavior 
4.1 Abstract 
Acute peripheral infection is associated with central and peripheral inflammation, increased 
oxidative stress, and behavioral components of sickness that include reduction in body weight 
and food intake, and decreased activity. Prolonged inflammation can lead to maladaptive 
behavioral symptoms including depressive-disorders and anxiety. The nutritional bioactive 
sulforaphane (SFN) displays potent anti-inflammatory properties against lipopolysaccharide 
(LPS)-induced inflammation in vitro, but has not been previously assessed in vivo during 
peripheral infection as a potential treatment for sickness behavior. Sulforaphane activates the 
nuclear factor E2-related factor 2 (Nrf2) pathway, which upregulates antioxidant response 
element genes (ARE) and lowers inflammation. In this study, LPS was used to mimic a 
peripheral infection. SFN was administered prior to LPS injection to examine whether SFN 
inhibited proinflammatory cytokines and reduced sickness behavior. We hypothesized that SFN 
would increase antioxidant response, reduce expression of proinflammatory cytokines in 
hippocampus and liver, and inhibit sickness behavior in mice challenged with LPS. In support of 
our hypothesis, SFN elevated ARE genes and reduced expression of proinflammatory mediators 
in hippocampus and liver, but surprisingly did not improve LPS-induced sickness response. 
These data indicate that SFN has an anti-inflammatory effect in both brain and periphery, but 
that longer exposure to SFN may be necessary to reduce sickness behavior.  
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4.2 Introduction 
 Peripheral inflammation has a well-established impact on the brain [1]. During acute 
infection, circulating cytokines trigger neuroinflammation through neural and humoral signaling 
pathways, resulting in increased cytokine expression in the brain that leads to behavioral 
changes indicative of a suppressed motivational state. These behavioral and physiological 
changes include decreased activity, lowered interest in socialization and pleasurable activities, 
and reduced food intake and body weight [2,3]. Although these adaptive sickness behaviors are 
a normal component of the innate immune response, amplified or prolonged 
neuroinflammation can lead to maladaptive sickness responses, increased absenteeism, and 
general feeling of discomfort [4]. Notably, previous studies have demonstrated that dietary 
interventions such as resveratrol and α-tocopherol reduced central inflammation and alleviated 
sickness behavior in mice treated with LPS [5,6]. These studies and others suggest that 
nutritional supplements are useful to mitigate the molecular and behavioral changes that occur 
during acute infection [5,7].  
 Oxidative stress results from reactive oxygen and nitrogen species that are generated 
during peripheral infection by complexes such as inducible nitric oxide synthase (iNOS) and 
NADPH oxidase 2 (NOX2), thus triggering the activation of redox-responsive inflammatory 
pathways. The brain is highly sensitive to oxidative damage, and minimizing oxidative stress 
through nutritional or pharmacological means has been proposed as a method of promoting 
long-term brain health [8]. Sulforaphane (SFN), a bioactive derived from broccoli, increases 
endogenous antioxidant response by upregulating genes containing the antioxidant response 
element (ARE) through activation of the transcription factor nuclear factor E2-related factor 2 
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(Nrf2). Elevated ARE gene expression in the periphery and brain is protective against cellular 
and tissue damage associated with and environmental toxins and other highly oxidative 
conditions [9,10]. In addition to its well-described antioxidant properties, the Nrf2/ARE 
pathway has also been reported to have anti-inflammatory effects in cell culture and animal 
models [11]. SFN is readily absorbed and can be administered in dietary or supplemental form, 
making it a potential therapeutic candidate for mitigating inflammation and oxidative stress 
associated with peripheral infection. However, the effects of SFN on acute sickness response 
have not been reported. The objective of this study was to determine whether SFN treatment 
reduces acute peripheral and central inflammation and inhibits sickness behavior following a 
LPS challenge. We hypothesized that SFN would upregulate ARE genes, and improve LPS-
induced sickness behavior by reducing proinflammatory cytokines in periphery and brain. 
 
4.3 Materials and Methods 
Animals and experimentation 
 Adult (4-6 month-old) male BALB/c mice reared in-house were individually housed in a 
temperature controlled environment with a reversed phase 12 h light:dark cycle (lights out at 
09:00 h). Mice were handled 1-2 min per day for one week prior to behavior testing. All studies 
were carried out in accordance with United States National Institutes of Health guidelines and 
were approved by the University of Illinois Institutional Animal Care and Use Committee.  
Sulforaphane (LKT Laboratories, St. Paul, MN) was dissolved in sterile saline immediately 
prior to experimentation. To assess if SFN upregulated ARE genes in liver and hippocampus in a 
time-dependent manner, a single dose of SFN (50 mg/kg) was administered i.p. and mice were 
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euthanized 2, 4, 6, or 8 h after injection. In subsequent studies, SFN (50 mg/kg) or saline was 
administered i.p. daily for 3 days with injections 24 h apart. On day 3, SFN and LPS (1 µg, i.p.) 
were co-administered. Escherichia coli LPS (serotype 0127:B8, Sigma, St. Louis, MO) was 
dissolved in sterile saline prior to injection. Treatments were administered during the first hour 
after onset of the dark phase of the light:dark cycle.  
 
Sickness response  
 
 Lipopolysaccharide injection mimics peripheral infection, resulting in adaptive sickness 
response [6]. To determine whether SFN inhibited LPS-induced sickness response, we assessed 
food intake, body weight, and locomotor activity. Home cage locomotor activity was assessed 6 
h after LPS. Mice were maintained in their home cage and locomotor activity was video-
recorded for 5 min. The cage was divided into four equal quadrants on the video records for 
scoring, and the number of line crossings (all 4 paws crossing into a new quadrant) and rearings 
(2 paws off the ground) were counted by an investigator blinded to the treatments.  
 
Tissue collection and analysis 
Animals were euthanized via CO2 asphyxiation 6 h after LPS and perfused with sterile ice-
cold saline. Brain and liver were rapidly removed and dissected sections were flash frozen.  All 
tissues were stored at -80°C until further processing for analysis. 
 To assess changes in gene expression, RNA was isolated from tissues using E.Z.N.A Total 
RNA kits according to manufacturer’s instructions (Omega Biotek, Norcross, GA). Synthesis of 
cDNA was carried out using a high capacity RT kit (Applied Biosystems, Grand Island, NY). Real-
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time quantitative RT-PCR (qPCR) was performed to detect changes in mRNA expression of ARE 
genes NQO1 (Mm.PT.58.9609207) and HMOX1 (Mm.PT.58.9675808). IL-1β 
(Mm.PT.58.41616450), IL-6 (Mm.PT.58.13354106), iNOS (Mm.PT.58.5680554), and CYBB 
(Mm.PT.58.11318181) were used to detect if proinflammatory mediators were reduced by SFN. 
All genes were analyzed using PrimeTime qPCR Assays (Integrated DNA Technologies, Coralville, 
IA) and were compared to the housekeeping control gene GAPDH (Mm.PT.39.a.1) using the 2-
ΔΔCt calculation method as previously described [12]. Data are expressed as fold change relative 
to controls.  
 Protein was extracted by homogenizing tissue in lysis buffer containing 20 mM Tris-Cl (pH 
7.8), 150 mM NaCl, 1 mM EDTA, 1% IGEPAL, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM 
sodium orthovanadate, 5 mM sodium fluoride, and protease inhibitor cocktail (Sigma, St. Louis, 
MO).  Protein concentration was determined using the DC Protein Assay (Bio-Rad, Hercules, 
CA). IL-1β protein was quantified using a commercially available ELISA (R&D Systems, 
Minneapolis, MN) according to the manufacturer’s instructions.  
 
Statistical analyses 
 All data were analyzed using Statistical Analysis System (SAS, Cary, NC). Data were subjected 
to two-way analysis of variance (ANOVA) for main effects of SFN, LPS, and 2-way interactions. 
When ANOVA revealed a significant interaction, post hoc Student’s t test using Fisher’s least 
significant differences was used to determine mean separation. All data are expressed as 
means ± SEM. 
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4.4 Results 
SFN increased ARE genes in liver and hippocampus 
Increased endogenous antioxidant response following SFN exposure is thought to provide 
cellular protection [13]. Previous studies have indicated that SFN upregulates ARE genes in liver 
and brain through Nrf2 activation [14-16]. Consistent with these reports, the current study 
revealed that a single injection of SFN increased transcription of the NQO1 in the liver at 2 h (p 
< 0.05) and 4 h (p < 0.01)  and increased HMOX1 at 2 h (p < 0.0001), 4 h (p < 0.001), and 8 h (p < 
0.001) (Figure 4.1). In hippocampus, SFN increased NQO1 and HMOX1 at 8 h (p < 0.05 for each).  
 
SFN reduced LPS-induced proinflammatory mediators in liver 
The liver is the primary detoxification organ for LPS, where hepatic macrophages scavenge 
LPS [17]. LPS evoked a robust increase in proinflammatory cytokines IL-1β (p < 0.0001) and IL-6 
(p < 0.001) in the liver (Figure 4.2). SFN reduced LPS induced IL-1β (SFN x LPS, p < 0.05) and IL-6 
mRNA (SFN x LPS, p < 0.01). In order to assess if the changes in mRNA were reflected by 
changes in protein, IL-1β protein was measured. SFN reduced LPS-induced IL-1β protein in liver 
(SFN, p < 0.05; LPS p < 0.01).  
LPS also upregulated cytochrome b-245 β (CYBB; p < 0.05), a functional subunit of the 
superoxide-producing NOX2 complex that is involved in the phagocytic capacity of 
macrophages. While CYBB mRNA appeared to be reduced in SFN-treated mice, the effect was 
not significant (p = 0.17).  
 
 
63 
 
SFN reduced proinflammatory mediators in hippocampus  
 Intraperitoneal injection of LPS is associated with elevated proinflammatory cytokine 
expression in the hippocampus which can cause cognitive and behavioral impairment [18]. To 
determine whether peripherally administered SFN could attenuate inflammation in the 
hippocampus, IL-1β and IL-6 were measured 6 h after a peripheral LPS injection. LPS increased 
IL-1β (p < 0.0001) and IL-6 (p < 0.05) mRNA in hippocampus (Figure 4.3). SFN reduced LPS-
induced IL-1β (SFN x LPS interaction, p < 0.05) but did not affect IL-6. SFN also lowered basal 
and LPS-induced iNOS in the hippocampus (p < 0.05). We were unable to detect Il-1β and IL-6 
protein in the brain due to concentrations lower than the assay detection limit.  
 
SFN did not improve sickness response in LPS-treated mice 
 Because inflammatory cytokine signaling in the brain causes adaptive sickness behaviors, 
we assessed food intake, body weight, and locomotor activity 6 h after LPS (Figure 4.4). Food 
intake decreased in all mice treated with LPS (p < 0.0001). The combination of SFN and LPS also 
resulted in lower food intake (SFN x LPS p < 0.05). Body weight was decreased 6 h after LPS (p < 
0.05). Locomotor activity was decreased in mice in mice treated with LPS (p < 0.0001). SFN did 
not improve locomotor activity in LPS-treated mice.  
 
4.5 Discussion 
The immunological changes that occur during acute peripheral infection cause 
neuroinflammation and sickness behaviors that negatively impact productivity and general 
physical and psychological well-being [19,20]. The dietary bioactive SFN is a potent inducer of 
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endogenous antioxidant response through the Nrf2 pathway, and is known to have anti-
inflammatory effects in vitro [21,22]. The present study provides additional evidence that SFN 
upregulates antioxidant Nrf2 target genes and reduces central and peripheral inflammation. 
However, despite the lowered inflammatory mediators, SFN did not mitigate acute LPS-induced 
sickness behavior.  
Liver macrophages are critical immune cells for detoxification and production of 
proinflammatory signaling mediators. In the present study, a robust inflammatory response to 
LPS was evident in the liver, resulting in increased IL-1β, IL-6, and cytochrome-b 245 β. 
Importantly, SFN reduced hepatic IL-1β and IL-6, demonstrating its ability to decrease 
peripheral inflammatory mediators. Previous studies have reported that SFN activates the Nrf2 
pathway in liver, resulting in cellular defense against oxidative damage, environmental toxins, 
and carcinogens [16,23,24]. The present data provide additional evidence that SFN has an anti-
inflammatory effect on the liver during acute LPS exposure.  
Because neuroinflammation during peripheral infection has a pronounced effect on sickness 
behavior, we were particularly interested to see whether SFN lowered neuroinflammation. In 
this study, SFN reduced LPS-increased hippocampal IL-1β mRNA, supporting our hypothesis that 
SFN has anti-inflammatory effects on the brain. Because central IL-1β also indirectly increases 
oxidative stress by upregulating iNOS activity, we measured iNOS mRNA and found that SFN 
lowered both basal and LPS-induced expression of iNOS. Surprisingly, this reduction in 
neuroinflammation did not improve sickness behavior. This is likely attributed to the fact that 
although a significant reduction in neuroinflammatory markers was apparent, SFN did not 
completely inhibit neuroinflammation (i.e. IL-6 was still elevated). Additionally, while it has 
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been reported that peripherally administered SFN crosses the blood brain barrier and can be 
detected in hippocampus within minutes of injection [25], it is possible that the concentrations 
that the brain is exposed to are too low or transient to influence the neuroinflammatory 
pathways that mediate sickness behavior. Another possible reason for the lack of improvement 
in sickness behavior is that while SFN reduced IL-1β in hippocampus, this reduction may not 
have occurred in other regions of the brain. In this study, we chose to focus on the 
hippocampus, as the hippocampus is densely populated with microglia, a cell type that is 
known to be involved in the proinflammatory cytokine production that facilitates sickness 
behavior [26]. Furthermore, microglia are highly sensitive to the anti-inflammatory effects of 
SFN in vitro [27]. Distinct regional differences in ARE gene expression and neuroinflammation 
following SFN treatment have not been reported and may merit further study.  
 The bidirectional signaling aspect of the immune and nervous systems implies that 
reduction of peripheral inflammation can reduce neuroinflammation [19,28]. Several studies 
have reported that the dietary antioxidants α-tocopherol, resveratrol, or luteolin administered 
to mice prior to a peripheral immune stimulus mitigated neuroinflammation and inhibited 
sickness behavior [5,6,29,30], In contrast, while SFN also reduced neuroinflammatory markers, 
it did not improve locomotor activity or other measures of sickness response. While it is 
tempting to speculate that longer exposure to SFN may be able to overcome the challenges of 
acute inflammatory response, previously we demonstrated that a 4 week exposure to dietary 
broccoli (a known source of SFN) did not improve sickness behavior in mice 24 h after LPS [31]. 
However, dietary broccoli did not reduce elevated brain IL-1β, and it is possible that 
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supplemental SFN, such as administered in the present studies, would have a greater effect on 
sickness behavior during the 24 h recovery period following LPS.  
In summary, the data presented here indicate that the anti-inflammatory peripheral effects 
of SFN may be more impactful than the effects in the brain. SFN’s peripheral effects may be 
especially relevant to the chronic inflammatory conditions encountered during stress and 
normal aging.  
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4.6 Figures 
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Figure 4.1. SFN increased ARE genes in liver and hippocampus in a time-dependent manner. (A-
B) SFN increased NQO1 and HMOX1 in liver. (C-D) SFN increased NQO1 and HMOX1 in 
hippocampus. Bars represent means ± SEM (n = 6-7). * indicates significant main effect of LPS (p 
< 0.05).  
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Figure 4.2. SFN reduced LPS-induced IL-1β and IL-6 in liver. (A-B) SFN reduced LPS-increased IL-
1β mRNA and protein in liver. (C) SFN reduced LPS-induced IL-6. (D) LPS increased CYBB. Bars 
represent means ± SEM (n = 6-8). * indicates significant main effect of SFN and + signifies main 
effect of LPS (p < 0.05). Means with different letters are significantly different from each other 
(p < 0.05). 
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Figure 4.3. SFN reduced IL-1β and iNOS mRNA in hippocampus. (A) SFN reduced LPS-induced IL-
1β mRNA hippocampus. (B) LPS increased IL-6. (C) CYBB was not affected by SFN or LPS. (D) SFN 
reduced iNOS in hippocampus. Bars represent means ± SEM (n = 6-8). * indicates significant 
main effect of SFN and + signifies main effect of LPS (p < 0.05). Means with different letters are 
significantly different from each other (p < 0.05). 
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Figure 4. 4. SFN did not improve sickness response after LPS. (A) Food intake was reduced by 
LPS.  (B) Body weight was decreased in LPS-treated mice. (C-D) Locomotor activity was reduced 
in LPS-treated mice. Bars represent means ± SEM (n = 6-8). * indicates main effect of LPS (p < 
0.05). Means with different letters are significantly different from each other (p < 0.05).  
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Chapter 5- Dietary broccoli mildly improves neuroinflammation in aged mice 
but does not reduce lipopolysaccharide-induced sickness behavior1 
5.1 Abstract 
Aging is associated with oxidative stress and heightened inflammatory response to 
infection. Dietary interventions to reduce these changes are therefore desirable. Broccoli 
contains glucoraphanin, which is converted to sulforaphane (SFN) by plant myrosinase during 
cooking preparation or digestion. SFN increases antioxidant enzymes including NAD(P)H 
quinone oxidoreductase (NQO1) and heme oxygenase I (HMOX1) and inhibits inflammatory 
cytokines. We hypothesized that dietary broccoli would support an antioxidant response in 
brain and periphery of aged mice and inhibit lipopolysaccharide-induced inflammation and 
sickness. Young adult and aged mice were fed control or 10% broccoli diet for 28 days prior to 
an intraperitoneal LPS injection. Social interactions were assessed 2, 4, 8, and 24 h following 
LPS, and mRNA quantified in liver and brain at 24 h. Dietary broccoli did not ameliorate LPS-
induced decrease in social interactions in young or aged mice. Interleukin (IL)-1β expression 
was unaffected by broccoli consumption but was induced by LPS in brain and liver of adult and 
aged mice. Additionally, IL-1β was elevated in brain of aged mice without LPS. Broccoli 
consumption decreased age-elevated cytochrome b-245 β, an oxidative stress marker, and 
reduced glial activation markers in aged mice. Collectively, these data suggest that 10% broccoli 
diet provides a modest reduction in age-related oxidative stress and glial reactivity, but is 
1 This chapter appeared in its entirety in Nutrition Research and is reprinted with the permission of the publisher. 
The article is available from http://www.sciencedirect.com using DOI:10.1016/j.nutres.2014.10.001. 
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insufficient to inhibit LPS-induced inflammation. Thus, it is likely that SFN would need to be 
provided in supplement form to control the inflammatory response to LPS. 
 
5.2 Introduction 
Aging is accompanied by chronic low-grade inflammation and increased oxidative stress, 
both of which are common factors in the pathology of chronic diseases [1,2]. Chronic 
inflammation leads to cognitive deficits and increases likelihood of developing 
neurodegenerative disease [3]. The aging brain is highly sensitive to inflammatory mediators 
generated in the periphery, evidenced by the molecular and behavioral changes that follow a 
peripheral immune stimulus such as infection, lipopolysaccharide (LPS) endotoxin, or stress [4-
6]. In fact, LPS-challenged aged mice exhibit exacerbated inflammation in the brain compared 
to adult mice [6,7]. Exaggerated expression of inflammatory mediators associated with immune 
activation in the aged signifies a need to identify interventions that attenuate age-related 
inflammation and oxidative stress both centrally and peripherally.  
 The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway is the primary transcriptional 
regulator of the cellular antioxidant response and is increasingly implicated in longevity and 
protection from inflammation. Declining Nrf2 activity may also be involved in the deleterious 
neurocognitive decline associated with aging [8-10]. The broccoli-derived bioactive 
sulforaphane (SFN) elicits activation of the Nrf2 antioxidant pathway, which protects tissues 
from toxic and carcinogenic insult by promoting transcription of genes containing the 
antioxidant response element (ARE) [11-13]. Due to the cytoprotective nature of Nrf2, 
activation of the Nrf2 pathway may be a good therapeutic target for reducing oxidative and 
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immune stress associated with chronic low-grade inflammation. In addition to evoking a Nrf2-
dependent antioxidant response, SFN also displays anti-inflammatory effects in vitro, which 
generates further interest in SFN and foods rich in SFN as potential therapeutic candidates for 
chronic inflammatory diseases [14,15]. As highlighted in a recent review article, the beneficial 
effects of sulforaphane have also been demonstrated in a number of experimental animal 
models, with evidence strongly suggesting that sulforaphane is a versatile treatment for 
inflammation and oxidative stress [16]. 
 Significant advances have been made in understanding the biochemical mechanisms 
underlying SFN-mediated activation of Nrf2 and its physiological effects, but minimal research 
has examined whether whole broccoli consumption influences age-associated inflammation. 
Broccoli provides a rich dietary source of vitamins, minerals, and flavonoids, but the unique 
nature of its health-promoting benefits, including cancer prevention and increased endogenous 
antioxidant production, have been associated with its naturally high levels of glucoraphanin 
[17-19]. Glucoraphanin is enzymatically hydrolyzed to the bioactive isothiocyanate SFN during 
crushing, chewing, or digestion of broccoli. Frequent intake of broccoli is associated with 
lowered risk of cancer and elevation of antioxidant enzymes [20,21]. Therefore, clinical 
research involving dietary supplementation with broccoli has focused primarily on 
chemoprevention and detoxification through activation of Phase II enzymes. Despite the 
accumulating evidence that SFN reduces inflammatory markers in cell culture and protects 
against oxidative stress during brain injury in vivo, the effects of dietary broccoli on peripheral 
and central inflammation in adult and aged animals have not been thoroughly investigated.  
Our objective was to examine whether dietary broccoli reduces LPS-induced inflammatory 
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markers in brain or liver of aged mice, and whether dietary broccoli could alter the sickness 
behavior response to LPS. We hypothesized that dietary broccoli would support an antioxidant 
response in brain and periphery of aged mice and inhibit LPS-induced inflammation and 
sickness behavior. In order to test this hypothesis, we used a pre-clinical murine model to 
investigate whether four weeks of dietary supplementation was sufficient to decrease markers 
of inflammation and reduce sickness behavior in adult and aged mice challenged with LPS. 
Sickness behavior and molecular inflammatory response has been well-characterized in our 
model of LPS-challenged aged mice, and these measurements will provide useful information 
for determining if broccoli supplementation attenuates behavioral complications of 
inflammation. A reduction in LPS-induced proinflammatory markers in the broccoli-
supplemented mice would indicate that broccoli is a suitable dietary addition to temper 
inflammation.   
 
5.3 Methods and Materials 
Animals and experimental diets 
 Adult (4-month-old) and aged (18-month-old) BALB/c mice reared in-house were 
individually housed in a temperature controlled environment with a reversed phase light:dark 
cycle (lights on 8:00 pm). During the 28-day experimental period, mice were given ad libitum 
access to water and diet consisting of AIN-93M or AIN-93M + 10% freeze-dried broccoli (Table 
1). Soy oil was replaced with corn oil to mitigate any potential anti-inflammatory effects derived 
from increased omega-3 fatty acid content of soy oil. The broccoli used in the diet provided 
5.22 µmol SFN/g as determined by laboratory hydrolysis using the methods described by Dosz 
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and Jeffery [22]. Therefore, it is estimated that mice fed the 10% broccoli diet were exposed to 
0.5 µmol glucoraphanin per g of diet consumed, providing up to 0.5 µmol SFN/g, depending 
upon the extent of glucoraphanin hydrolysis. To diminish the potential for degradation of 
glucosinolates from the broccoli-containing diet, both diets were replaced every other day. 
Body weight (BW) was recorded weekly. Mice were handled 1-2 min per day for one week prior 
to behavior testing. All studies were carried out in accordance with United States National 
Institutes of Health guidelines and were approved by the University of Illinois Institutional 
Animal Care and Use Committee.  
 
Immune challenge 
Escherichia coli LPS (serotype 0127:B8, Sigma, St. Louis, MO) was dissolved in sterile saline 
prior to experimentation. On day 29 of dietary intervention, mice from each diet group (n = 7) 
were given LPS (0.33 mg/kg BW) or saline intraperitoneally (i.p.). Treatments were 
administered during the first hour after onset of the dark phase of the light:dark cycle.  
 
Behavioral testing 
 To determine whether broccoli diet reduced sickness behavior, social exploratory behavior 
was assessed in all mice 2, 4, 8, and 24 h after treatment, as previously described in detail [23]. 
Base-line social exploratory behavior was determined 24 h prior to treatment and was used as a 
basis of comparison for calculating percent baseline time spent investigating a novel juvenile. A 
novel juvenile conspecific mouse was placed inside a protective cage before being placed in the 
home cage of the experimental mouse. Social interactions were video-recorded for 5 min and 
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scored by an experimenter blinded to the treatments. Social exploration is determined as the 
amount of time spent investigating the juvenile (sniffing, in close proximity to the juvenile) and 
is reported as percent of baseline.   
 
Tissue collection and analysis 
Animals were euthanized via CO2 asphyxiation 24 h after treatment, perfused with sterile 
ice-cold saline, then brain and liver tissues were dissected and flash frozen.  All tissue samples 
were stored at -80°C until further processing for analysis. 
 RNA was isolated using E.Z.N.A. Total RNA kits according to the manufacturer’s instructions 
(Omega Biotek, Norcross, GA). Synthesis of cDNA was carried out using a high capacity RT kit 
(Applied Biosystems, Grand Island, NY) according to the manufacturer’s instructions. Real-time 
quantitative RT-PCR (qPCR) was performed to detect changes in mRNA expression of ARE genes 
NQO1 (Mm.PT.56a.9609207) and HMOX1 (Mm.PT.56a.9675808) and the transcription factor 
Nrf2 (Mm.PT.56a.29108649M). The inflammatory cytokine IL-1β (Mm.PT.56a.41616450) was 
used as a marker to detect if inflammatory cytokine production was reduced in animals fed the 
broccoli diet. The glial activation markers GFAP (Mm.PT.56a.6609337.q), CD11b 
(Mm.PT.56a.9189361), MHC-II (Mm.PT.56a.43429730), and CX3CR1 (Mm.PT.56a.17555544) 
were used to determine whether astrocyte and microglial activation was affected by dietary 
intervention. All genes were analyzed using PrimeTime qPCR Assays (Integrated DNA 
Technologies, Coralville, IA) and were compared to the housekeeping control gene GAPDH 
(Mm.PT.39.a.1) using the 2-ΔΔCt calculation method as previously described [24]. Data are 
expressed as fold change versus control diet mice treated with saline.  
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Statistical analyses 
 All data were analyzed using Statistical Analysis System (SAS, Cary, NC). Data were subjected 
to three-way analysis of variance (ANOVA) for main effects of age, diet, and LPS, and all 2- and 
3-way interactions. Where ANOVA revealed a significant interaction, post hoc Student’s t test 
using Fisher’s least significant differences was used to determine mean separation. All data are 
expressed as means ± standard error of mean (SEM). 
 
5.4 Results 
LPS increased glial markers while broccoli diet reduced GFAP and increased CX3CR1 mRNA in 
aged mice 
ARE gene expression is elevated in glial cells treated with SFN, indicating that glia may be 
sensitive to the protective benefits of SFN [25-27]. Because glial cells are also the predominant 
producers of proinflammatory mediators in brain, we measured expression of several markers 
of glial reactivity. Glial fibrillary acidic protein (GFAP) was elevated in brain of aged mice (p < 
0.001). Interestingly, broccoli diet lowered expression of GFAP in aged mice (Age x Diet 
interaction, p < 0.05) (Figure 5.1). To determine whether dietary broccoli could decrease 
neuroinflammation in response to systemic LPS, we measured markers of glia reactivity in LPS 
or saline treated mice. GFAP was increased in mice given LPS (p < 0.05). The microglial 
activation markers MHC-II and CD11b were quantified to examine reactivity in microglia. MHC-II 
expression was not changed 24 h following LPS, but LPS did induce higher CD11b expression (p 
< 0.0001). Diet had no effect on the expression of these microglial activation markers at 24 h 
after LPS treatment.  
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Fractalkine receptors (CX3CR1) expressed on microglia provide a regulatory mechanism by 
which microglia activity is regulated in brain. Aged mice reportedly have decreased CX3CR1 
resulting in decreased immunoregulatory signals to microglia leading to prolonged activation 
state following LPS [28]. CX3CR1 was induced by LPS (p < 0.05). Broccoli diet increased CX3CR1 
mRNA in aged mice (Age x Diet interaction; p < 0.05), suggesting another potential role of 
dietary broccoli in reducing glial reactivity.  
 
Broccoli diet did not attenuate LPS-induced reduction in social interactions 
To evaluate whether dietary broccoli reduced sickness after an acute peripheral immune 
challenge, we used the social exploratory test. LPS decreased social investigation 2, 4, 8, and 24 
h after LPS (LPS x Time interaction, p < 0.05) (Figure 5.2). Broccoli diet did not significantly 
influence social behavior.  
 
Age and LPS increased proinflammatory IL-1β mRNA in liver and brain 
Because IL-1β is known to play a significant role in sickness behavior, IL-1β expression 
was quantified in both central and peripheral tissues [29,30]. Aged mice had elevated basal IL-
1β in brain (Figure 5.3). These results are consistent with previous studies that demonstrated 
increased IL-1β in aged mice and exaggerated expression to LPS [3,6,31]. LPS significantly 
increased IL-1β mRNA in liver and brain of both adult and aged mice (p < 0.001). The broccoli 
diet did not affect brain IL-1β levels in control or LPS-treated mice. Although broccoli diet 
appeared to decrease IL-1β in control and LPS-treated aged mice, there was no main effect of 
diet and the Age x Diet interaction was not significant (p = 0.12).  
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CYBB was elevated in liver of aged mice 
 NADPH oxidase generates neurotoxic and hepatotoxic reactive oxygen species that have 
been implicated in development of chronic disease [32,33]. Cytochrome B-245 β (CYBB) is a 
functional component of the NADPH oxidase system that contributes to release of free radicals 
from phagocytic cells. We examined whether broccoli attenuated CYBB expression. An Age x 
Diet interaction revealed that CYBB expression was increased in the liver of aged control 
animals compared to adult control animals (p < 0.05), and broccoli diet tended to prevent the 
elevation in CYBB in aged mice (p < 0.10) (Figure 5. 4). 
 
Broccoli did not significantly influence the Nrf2 pathway 
 Several studies demonstrate that broccoli consumption increases Nrf2-inducible antioxidant 
enzyme activity in colon and liver tissue, presumably through SFN absorbed from dietary 
broccoli [34]. Importantly, SFN also induces Nrf2 antioxidant pathway in brain leading to 
increased ARE gene expression that provides neuroprotective benefits [35,36]. To determine 
whether this anti-inflammatory effect is exhibited in brain or periphery of aged mice following 
dietary broccoli consumption, we measured Nrf2 gene expression after four weeks of control or 
broccoli diet in mice given LPS or saline. Broccoli diet marginally increased Nrf2 expression in 
brain of LPS-treated mice, although this increase did not reach significance (p < 0.10). LPS did 
not induce Nrf2 expression at 24 h post-treatment (Fig. 5). Neither diet, treatment, nor age 
effected Nrf2 expression in liver.  
NQO1 increased in liver of aged mice (p = 0.05). Analysis of brain tissue revealed an Age x 
Diet x Treatment interaction (p < 0.05), where increased NQO1 expression was most evident in 
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mice fed broccoli diet and given LPS. LPS increased HMOX1 expression in brain and liver (p < 
0.01), but dietary broccoli had no affect (Figure 5.6). 
 
5.5 Discussion 
 Dietary interventions that reduce aging-related inflammation garner significant research 
interest. While broccoli and broccoli sprouts are drawing increased interest from medical and 
nutritional scientists, much of the research focus has been centered on the benefits of dietary 
broccoli for cancer treatment and prevention. In the present studies, we focused on the anti-
inflammatory properties of compounds found in whole broccoli and sought to determine 
whether a broccoli-supplemented diet was beneficial for attenuating systemic and central 
inflammation in aged mice. In these studies, four weeks of feeding a 10% freeze-dried broccoli 
diet mildly improved markers of glial reactivity in aged mice and tended to prevent age-induced 
increase in hepatic CYBB. In contrast to in vitro studies in which supra-physiological 
concentrations of SFN reduced LPS-induced proinflammatory cytokines, dietary broccoli did not 
reduce proinflammatory cytokines in mice that were challenged with LPS.  
CYBB expression is regulated by a number of transcription factors, including the redox 
sensitive nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB).  Our data and 
others suggest that CYBB expression increases with age, which may contribute to increased 
oxidative stress that occurs with age [33,37]. While CYBB expression levels are not a direct 
indication of ROS, transcriptional regulation of CYBB has a marked impact on ROS production 
[38,39]. We demonstrate that dietary broccoli may prevent the age-induced elevation in CYBB, 
which may hold significance for reducing increased oxidative stress associated with aging.   
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Using both in vitro and in vivo models, SFN conveys Nrf2-dependent neuroprotective effects 
to cultured astrocytes and microglia and to brain regions including hippocampus, striatum, and 
cortex [36,40,41]. Consistent with previously published data, we saw transcriptional increases 
in GFAP in aged mice, suggesting increased astrocyte reactivity [42]. Interestingly, broccoli diet 
down-regulated LPS-induced GFAP expression in aged mice suggesting that astrocytes may be 
sensitive to low circulating levels of SFN achieved from consuming dietary broccoli. This finding 
may demonstrate that based on the juxtaposition of astrocytes with brain blood vessels, 
astrocytes may be better positioned to respond to the anti-inflammatory effects of SFN. To our 
knowledge, this is the first evidence to suggest that dietary broccoli influences GFAP. In light of 
this, it would be interesting to further examine the effects of feeding a broccoli-supplemented 
diet to mice on changes in surface expression of glial reactivity markers in primary culture. This 
has been tested to some extent with SFN, but to our knowledge, not with dietary broccoli.  We 
also observed evidence of microglia or perivascular macrophage reactivity. Increased 
expression of the genetic marker for microglia/macrophage activation, CD11b, was expectedly 
increased in animals treated with LPS. Expression of CD11b was unaffected by diet suggesting 
that neither microglia nor brain resident macrophages were responsive to the beneficial effects 
of a broccoli diet in our model. This was surprising, given that microglia and macrophages are 
robust producers of reactive oxygen and nitrogen species during inflammatory stimulation. 
However, these cells are also quite sensitive to LPS induced inflammation and the dose of LPS 
used may have overwhelmed the beneficial effects of dietary broccoli. These data indicate that 
gliosis induced by a peripheral stimulus is aggravated by age, and that dietary broccoli may 
reduce aging-associated glial reactivity.  
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The fractalkine ligand (CX3CL1) and fractalkine receptor (CX3CR1) is an important regulatory 
system for tempering the microglial response following activation from endogenous and 
exogenous immune stimuli. Indeed, mice with a genetic deletion of CX3CR1 have an 
exaggerated microglial inflammatory response and increased duration of sickness behavior 
compared to wild-type mice. CX3CR1 knockout mice have a similar response to LPS treatment 
as to that observed in aged animals [28,43,44]. Additionally, it has been demonstrated that LPS 
decreases CX3CR1 at both the mRNA and protein level in microglia [28]. We observed an LPS-
induced decrease in CX3CR1 expression in our model that was prevented in aged animals given 
LPS and fed broccoli diet. These data suggest that aged animals that consume dietary broccoli 
may have suppressed microglial activation compared to animals that do not consume broccoli 
in the diet and therefore may have improved long term brain health, e.g. improved neuron 
survival and increase in neurogenesis, when confronted with infectious disease due to potential 
suppression of microglial hyperactivity that has been described in aged mice [28,45]. 
Consumption of broccoli has not been previously reported to upregulate CX3CR1 and it is 
important to note that additional research is required to determine if the increase in mRNA 
translates to cell surface expression on primary microglia and whether this change promotes 
long term brain health due to attenuated microglia activation.  
 Increased glia reactivity is accompanied by elevated IL-1β [44,46]. Since broccoli diet 
decreased markers of glial reactivity in aged mice, we examined IL-1β expression to determine 
if broccoli diet attenuated additional inflammatory mediators. IL-1β is a key inflammatory 
cytokine in both the peripheral and central immune response [47]. IL-1β induces sickness 
behaviors such as anorexia, decreased locomotion, and social activity when exogenously 
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administered while inhibition of IL-1β signaling attenuates sickness behaviors in response to LPS 
treatment [30,48,49]. For these reasons, we hypothesized that broccoli diet would exert an 
anti-inflammatory benefit by inhibiting IL-1β expression and this would attenuate LPS-induced 
sickness behaviors. In the present study, decreased social behavior was paralleled by increased 
IL-1β in brain, but there was no evidence that broccoli diet moderated LPS-induced sickness 
behavior. It is possible that the dose of LPS used (0.33 mg/kg) overwhelmed the anti-
inflammatory dietary effects of consuming broccoli. It is also likely that the anorexic effect of 
LPS-induced sickness limited broccoli intake, resulting in lowered SFN exposure. Indeed, we 
observed that 24 h food consumption was decreased in LPS-treated mice compared to saline 
controls (data not shown). SFN is metabolized and excreted rapidly following broccoli 
consumption, and metabolites are not retained in tissue past 24 h [50-52]. It seems plausible 
that diminished intake of broccoli during the 24 h sickness period could account for the lack of 
effectiveness against acute peripheral inflammation. Our findings are in contrast to other 
studies where dietary luteolin, resveratrol, or α-tocopherol and selenium improved LPS-induced 
sickness behavior in aged mice. Collectively these nutritional interventions suggest that dietary 
supplements are a viable therapeutic vehicle to ameliorate prolonged sickness in aged models 
[31,53,54]. A more successful approach may be to incorporate SFN in supplement form into the 
diet. In agreement with this approach, some studies have demonstrated reduced 
neuroinflammation using purified SFN given intraperitoneally at doses of 50 mg/kg, which is 
several-fold higher than could be reasonably obtained through the 10% broccoli diet [36,41]. It 
remains to be determined whether the concentrations of SFN that were necessary to achieve 
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reductions in inflammatory markers in these studies can be obtained through voluntary dietary 
consumption.  
 Broccoli was selected for this study because it is a frequently consumed glucoraphanin-
containing vegetable [55,56]. Although the SFN-precursor glucoraphanin is more concentrated 
in broccoli sprouts compared to broccoli, high glucosinolate content adds additional bitterness 
to the taste of the sprout, making it less palatable than broccoli [12,57]. Preparation of freeze-
dried broccoli has been optimized to preserve glucosinolates and prevent inactivation of 
myrosinase. This is particularly important because SFN is not stable and is more bioactive when 
fed to rats in its glucosinolate precursor form than when hydrolyzed prior to being fed to 
rodents [34]. Addition of 10-20% freeze-dried broccoli to rodent diet has been reported to 
increase activity of hepatic and colonic ARE enzymes [58-60]. In contrast to these reports, 10% 
broccoli diet utilized in our studies did not increase ARE genes in brain or liver tissue of aged 
mice. However, in this study, HMOX1 was induced by LPS, suggesting that this gene is activated 
in response to increased oxidative stress generated by LPS-induced inflammation [61]. HMOX1 
is an endogenous antioxidant that inhibits inducible nitric oxide synthase in LPS-stimulated 
macrophages, and higher HMOX1 mRNA and protein is associated with an anti-inflammatory 
macrophage phenotype [62-64]. Although HMOX1 is notable as part of the antioxidant cascade 
activated by Nrf2, HMOX1 mRNA expression was also responsive to inflammation induced by 
LPS. Induction of HMOX1 by LPS in our model was an expected component in agreement with 
findings indicating that, in addition to containing a Nrf2-inducible ARE promoter region, HMOX1 
is upregulated by the proinflammatory NFκB transcriptional pathway that is strongly activated 
by LPS [65]. Based on our findings, HMOX1 appears to be more transcriptionally responsive to 
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activation of NFκB during inflammation than to 10% broccoli diet. A 10% broccoli diet may be 
insufficient to elevate SFN levels in circulation to temper acute inflammation in mice. In 
agreement with this suggestion, Innamorato et al. reported that HMOX1 protein is induced in 
the brain by a high dose of SFN injected i.p. [36], but there are no published data reporting in 
vivo induction of HMOX1 transcription and translation following low doses of SFN such as that 
obtained when consuming broccoli supplemented diet. A clinical study that examined gene 
expression in gastric mucosa after consumption of broccoli soup reported that while several 
antioxidant genes were elevated in gastric mucosa, only a fraction of genes previously induced 
by SFN in vitro were altered by the broccoli soup [66]. It is evident that additional pre-clinical 
and clinical studies are needed to determine effective timing and dosage of broccoli inclusion in 
the diet. 
 Another explanation for the lack of ARE gene expression induced by broccoli diet is that 
other peripheral tissues, such as intestine or resident macrophages of the peritoneum,  may be 
more sensitive to broccoli supplemented diet. Several phamacokinetic studies report that SFN 
metabolites are widely distributed in tissues following orally administered SFN, but bioactivity 
in these tissues is not well-established and distribution of SFN does not appear to correlate with 
tissue-specific bioactivity [52,67]. Based on our findings, dietary broccoli is insufficient to 
upregulate HMOX1 and NQO1 in liver and brain. Future studies will help to determine if 
broccoli supplemented diets are more beneficial in low-grade peripheral inflammatory 
conditions than acute conditions such as LPS. 
An apparent limitation to this study is that reduced food intake is part of the natural 
sickness response to LPS. Decreased intake of dietary broccoli in LPS-injected mice on the final 
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day of the study may have interfered with acute effects that would have been apparent if the 
mice ate as usual. The overall lack of effects due to dietary broccoli may have been due to 
reduced food intake. 
In summary, we have demonstrated that consumption of a 10% broccoli diet mildly reduced 
neuroinflammation in aged mice by preventing upregulation reactive glia markers. However, 
we did not find evidence to support our hypothesis that LPS-induced inflammatory markers and 
sickness behavior could be attenuated by dietary broccoli. While these data do not support a 
role for broccoli consumption in suppressing sickness behaviors associated with an LPS-induced 
acute inflammatory response, they do not rule out that components found in broccoli, such as 
SFN, may be beneficial when consumed in pharmacological doses via supplementation. Taken 
together, our data suggest potential health benefits for the aged human population using 
dietary broccoli to improve the low-grade neuroinflammation that is associated with aging.  
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5.6 Figures and Tables 
  
AIN-93M 
AIN-93M + 
10% Broccoli 
Protein 14.7% 14.7% 
Carbohydrate 75.9% 75.9% 
Fat 9.4% 9.4% 
Freeze-dried broccoli 
(Brassica oleracea L. cv 
“Green Magic”)  
--  100 g 
Casein 140 g 113.6 g 
Corn Starch 495.7 g 473.8 g  
Maltodextrin 10 125 g 110.1 g 
Sucrose 100 g 99.1 g 
Cellulose 50 g 25.7 g 
L-Cystine 1.8 g 1.8 g 
Mineral Mix 35 g 35 g 
Vitamin Mix 10 g 10 g 
Choline Bitartrate 2.5 g 2.5 g 
Corn oil 40 g 36.5 g 
 
Table 5.1. Ingredient composition of the diets fed to micea,b 
a Broccoli was grown at the University of Illinois, Urbana. All other diet ingredients were 
purchased from Harlan Laboratories (Indianapolis, IN).  
b Nutrient content of broccoli was obtained from the USDA Nutrient Database for Standard 
Reference 
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Figure 5.1. LPS increased glial markers while broccoli diet reduced GFAP and increased CX3CR1 
mRNA in aged mice. (A) GFAP was elevated by age (p < 0.001) and by LPS (p < 0.05). Broccoli 
diet decreased GFAP in aged mice. (B) CX3CR1 increased with LPS (p < 0.05). Broccoli diet 
increased CX3CR1 in aged mice compared to adult controls. (C) CD11b was elevated by LPS. (D) 
No change was evident in MHC-II after LPS. Data are presented as means ± SEM (n = 5-7). 
Means with different letters are statistically significant. * p < 0.05 compared to adult saline 
controls. 
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Figure 5.2. LPS decreased social interactions similarly in mice fed control or broccoli 
supplemented diet. Data are means ± SEM (n = 5-7). * indicates LPS x time effect p < 0.05 
compared to saline controls. 
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Figure 5.3. IL-1β mRNA was increased in aged mice and all mice given LPS in liver and brain. (A) 
IL-1β was increased 24 h after LPS in liver (p < 0.001) (B) IL-1β was elevated in brain of aged 
mice (p < 0.01) and increased 24 h after LPS (p < 0.0001). Bars represent means ± SEM (n = 5-7). 
* p < 0.05 compared to adult saline controls. 
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Figure 5.4. CYBB was elevated in liver of aged mice. CYBB was elevated in the aged control diet 
group compared to adult controls (Age x Diet interaction, p < 0.05). In aged mice, broccoli diet 
tended to decrease CYBB compared to control diet (p < 0.10). Values are means ± SEM (n = 5-7). 
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Figure 5.5. Broccoli diet did not increase Nrf2 mRNA. Broccoli and LPS tended to increase Nrf2 in 
brain 24 h after LPS (Age x Diet interaction p < 0.10). Data are represented as means ± SEM (n = 
5-7).  
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Figure 5.6. NQO1and HMOX1 in brain tissue were increased in aged mice and all LPS-treated 
mice. (A) NQO1 was increased in liver of aged mice (p = 0.05). HMOX1 was increased in liver 24 
h after LPS (p < 0.01).  (B) NQO1 was increased in brain of aged mice (p < 0.05) and was 
elevated 24 h after LPS (p < 0.01). Means with different letters are statistically significant (Age x 
Diet x LPS interaction p < 0.05). Bars represent means ± SEM (n = 5-7). * p < 0.05 compared to 
adult saline controls. 
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Chapter 6 – Summary and Significance 
Inflammation and oxidative stress are viewed by many to be the two most important 
factors that determine whether a person will experience healthy aging or pathological aging [1]. 
Inflammation and oxidative stress contribute to the pathogenesis of many chronic diseases of 
aging, including cardiovascular disease, diabetes, atherosclerosis, neurodegenerative disease, 
and others [2,3]. The striking prevalence of inflammation and altered redox balance in aging-
related disease pathology suggests that these factors may underlie molecular changes that 
occur during the normal aging process. In support of this concept, research has demonstrated 
that low-grade inflammation is also apparent in otherwise healthy aged individuals, 
dramatically increasing their risk of cognitive impairment, frailty, and chronic disease [1,4,5].  
The rapidly aging global population and parallel increase in aging-related disease has 
stimulated scientists to elucidate the molecular mechanisms that define aging [6,7]. 
Consequently, the volume of publications related to aging and inflammation has greatly 
expanded over the past two decades, advancing our understanding of the aging process and 
leading to more targeted approaches to promote healthy aging. The molecular changes that are 
evident during both pathological and non-pathological aging suggest that increasing age leads 
to excess proinflammatory signaling that is not countered by a sufficient anti-inflammatory 
response [8,9]. Furthermore, increased oxidative damage during aging indicates that 
endogenous antioxidant mechanisms do not provide adequate antioxidant activity to protect 
tissues from prolonged oxidative stress [10,11]. While the underlying causes of immune 
dysregulation in the elderly are not fully understood, it seems that this imbalance contributes 
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to a variety of physiological and psychological effects that lower the quality of life and increase 
the prevalence of chronic disease.   
Increased inflammation and oxidative stress are apparent in the aging brain as well as the 
peripheral immune system, leading to cognitive and behavioral impairment, delayed recovery 
time following an illness, and limited ability for self-care in the elderly population, Collectively, 
these factors increase hospitalizations and place a greater burden on family members and 
healthcare providers [12-14]. Clarifying the mechanisms that result in age-related immune 
imbalance and identifying preventative interventions are therefore critical aspects of aging 
research. This dissertation describes antioxidant and anti-inflammatory effects of the broccoli-
derived bioactive SFN on brain and behavior and implications for future aging research.  
The first aim of this study examined the effects of SFN on adult and aged primary microglia 
that were stimulated ex vivo with LPS. The results demonstrated that SFN increased expression 
of Nrf2 target genes and decreased LPS-induced proinflammatory mediators in adult and aged 
microglia. This is a significant finding, because microglial involvement is increasingly implicated 
in neuroinflammatory disorders related to aging, cognitive decline, and neurodegeneration [15-
17]. These results open the door to the possibility that SFN exposure may be able to alter the 
aged microglial phenotype in vivo. While our data indicated that the Nrf2/ARE pathway in aged 
microglia is sensitive to the antioxidant-enhancing properties of SFN, additional in vivo studies 
are needed to determine if stimulation of the Nrf2 pathway in the brain of aging mice supports 
an anti-inflammatory microglial phenotype and promotes long-term brain health.  
Based on our data demonstrating that SFN decreased proinflammatory mediators in 
microglia, the second aim of this study was to determine if SFN reduced neuroinflammation in 
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mice that had been injected with LPS. Sulforaphane influences the central and peripheral 
immune response, as indicated by reduced expression of the proinflammatory cytokine IL-1β in 
the hippocampus and liver of LPS-treated mice. While our data demonstrated that SFN reduced 
proinflammatory markers, it did not completely inhibit them, which likely explains why we did 
not see a change in sickness behavior. However, this study focused only on the acute molecular 
and behavioral changes in response to LPS, and the effects of supplemental SFN on chronic low-
grade inflammation that is associated with aging and cognitive impairment may be an 
interesting area for further investigation.  
The third aim of the study focused on the effects of broccoli-supplemented diet on 
peripheral and neuroinflammation in LPS-stimulated adult and aged mice. This study indicated 
that dietary broccoli had no overall effect on inflammatory markers in adult mice, but 
suggested that broccoli diet may lower markers of glial reactivity in aged mice. In the previous 
study, we demonstrated that multiple doses of peripherally administered SFN lowered LPS-
induced IL-1β expression in hippocampus of adult mice. Here, it is important to note that SFN 
obtained through dietary means has not been measured in the brain, and it is possible that SFN 
directly reaches the brain only when administered in high concentrations. However, bi-
directional communication between the immune system and the central nervous system is an 
important determinant of neuroinflammatory status during peripheral infection. 
Proinflammatory mediators that are generated in the periphery reach the brain through the 
neural and humoral signaling pathways, evoking a neuroinflammatory response [18,19]. This 
well-established communication network implies that inhibition of proinflammatory peripheral 
mediators also reduces the inflammatory signals that are sent to the brain. It is possible that 
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longer exposure to supplemental SFN could inhibit peripheral inflammatory mediators, thereby 
reducing neuroinflammation. This is of potential interest in aging studies, where chronic dietary 
exposure to a bioactive that reduces peripheral and central inflammation could preserve 
cognitive function.  
Anti-inflammatory dietary bioactives such as SFN can be valuable interventions to promote 
healthier aging. More research is needed in this area to identify additional molecular targets of 
SFN that may be beneficial in reducing inflammation, and to investigate anti-inflammatory 
effects using SFN combined with other Nrf2-activiating bioactives.  
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